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ABSTRACT

FLEXIBLE MODELING OF COMPETING RISKS AND CURE RATE
IN SURVIVAL ANALYSIS

Qi Jiang, Ph.D.,
Department of Mathematical Sciences
Northern Illinois University, 2015
Sanjib Basu, Director

Advancement in medical sciences has produced therapies with curative potential
for some diseases regarded as terminal in the past. Yet patients may simultaneously
be subject to multiple diseases, not all of which can be cured. When there is only
one disease in the context and that disease has a cure possibility, a rich class of cure
models can be built by taking into consideration the underlying mechanisms leading
to cure and relapse. We propose a class of flexible cure models that accounts for
uncertainties in such mechanisms. Our proposed model includes many existing cure
models as special cases and can be expressed in simpler mathematical forms than
existing models of similar objectives. We provide numerical examples to illustrate
the consequences of neglecting underlying mechanisms of cure and relapse and show
the ability of our proposed model to identify such mechanisms.
On the other hand, competing risks data arise if patients are exposed to more than
one disease. Modeling of competing risks data based on the cumulative incidence
functions approach has the advantage of providing direct inference on the survival
probabilities from each risk. We propose a flexible model that directly models the

cumulative incidence functions and automatically accounts for the possibility that one
or more of the diseases may be cured. We further develop regression models that can
be used to obtain direct inference of the effect of a covariate on the marginal failure
probability of each risk. We use a Bayesian approach for the analysis and provide
numerical examples to illustrate the performance of the proposed model.
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CHAPTER 1
INTRODUCTION

Cure from cancer is increasingly a reality for a proportion of cancer patients,
especially for those in early or moderate stage with less aggressive cancers. Advances
in treatment resulted in remarkable improvement in survival from cancer. According
to American Cancer Society [4], five-year relative survival rates from all cancers
increased from 49% in 1975–1977 to 68% in 2003–2009. The improvement in fiveyear relative survival varies by ethnicity, from 50% in 1975–1977 to 68% during 2003–
2009 for Whites compared with from 39% in 1975–1977 to 61% during 2003–2009
for African-Americans. The five-year relative survival rates also vary remarkably by
cancer site, 90% for female breast cancer, 100% for prostate cancer, 65% for colon
cancer, but only 18% for lung cancer, which is the leading cause of cancer mortality.
For patients at “local stage” where the invasive malignant cancer is confined entirely
to the organ of origin, the five-year relative survival rates are 99%, 90% and 54% for
breast, colorectal and lung cancers respectively.
Cure rate models provide generalization of standard survival models to allow a
nonnegative proportion of patients to be cured from cancer. Two types of model
that account for the cure fraction are the mixture cure model (Berkson and Gage [8])
and the bounded cumulative hazard (BCH) model (Yakovlev et al. [99], Yakovlev
and Tsodikov [100]). The cure fraction or probability of cure, c, is the asymptotic
value of the survival function S(t) as t → ∞.
A cancer patient may also have other diseases, such as heart disease, at the
same time, resulting in a competing risks setup. Competing risks data arise when
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subjects are simultaneously exposed to different causes of events. If the event is
terminal, such as death, then the occurrence of an event due to one specific cause
precludes the occurrence of events due to the other causes. In such cases, the
observed data on a subject consist of the pair (T, C), where T is the time to first
event, usually subject to censoring, and C is the index for a set of mutually exclusive
competing causes. Two fundamental quantities that can be identified from such data
are the cause-specific hazard function and the cumulative incidence function (CIF).
The joint distribution of (T, C) is completely specified through either one of these
two quantities. Traditionally, the competing risks data are studied by modeling
the cause-specific hazard function (Prentice et al. [80]). This approach has the
advantage that standard survival analysis methods, such as the Cox proportional
hazard model and the accelerated failure time model, can be readily applied and
such methods are implemented in all standard software. However, there has been
growing interest in the cumulative incidence function, which is frequently presented
in medical articles nowadays. Medical investigators are interested in studying the
event-specific failure probabilities and comparing the difference in the cumulative
incidence rates among different events. In addition, it is of interest to determine the
treatment effect and to identify prognostic factors for a particular type of failure
in presence of competing risks. Furthermore, a graphical plot of the cumulative
incidence function is more intuitive and appealing than a plot of hazard function.
As a result, the cumulative incidence function has been essential to decision making
(Pepe and Mori [76]).
While it is possible that a patient can be cured from one disease, he/she will
eventually fail from some other risks. This implies that the overall survival function
in presence of competing risks should necessarily be proper. There has been little
research done on the estimation of cure rate in the context of competing risks. Basu

3
and Tiwari [6] and Sarkar [85] developed competing risks cure models using the
mixture cure model and the bounded cumulative hazard model respectively. Their
models yield proper overall survival functions and provide better fits for the overall
survival. In terms of inference, however, both of their models are equivalent to
fitting separately a cure model and a regular survival model on each corresponding
risk.
In this dissertation, we propose an innovative competing risks model that directly
models the cumulative incidence functions for each competing risk. In addition, we
also propose a novel cure model that flexibly describes the behavior of the survival
time in non-cured patients. Our proposed competing risks model has several advantages. First, it gives a closed-form expression for the cumulative incidence function.
Second, it ensures that the sum of the cumulative incidence functions has a limit of
one, an important issue ignored in most existing models. Third, the model results
in a proper overall survival function. And finally, it has a distinct feature that it
automatically accounts for the possibility of cure of each risk. Our proposed cure
model has a mathematically closed form and includes several existing models as
special cases. Furthermore, it is stochastically ordered in terms of the parameter
and is analytically more tractable and more flexible than the existing models with
similar modeling objectives. The rest of this dissertation is organized as follows.
Chapters 2 and 3 are literature reviews on competing risks models and cure models.
We introduce our new cure model in Chapter 4 and our new competing risks model
in Chapter 5. We conclude with a discussion on future research in Chapter 6.

CHAPTER 2
COMPETING RISKS MODELS

2.1

Introduction

We assume that each subject is exposed to K mutually exclusive causes (or
risks) of a terminal event. The event is terminal in the sense that the occurrence
of the event due to one cause precludes the occurrence of the event due to other
causes. A terminal event can be death or first relapse in biomedical applications and
machine failure in engineering applications. Often, both terminal and non-terminal
events are observed. For example, we can observe both relapse (non-terminal) and
death (terminal) from the same cancer. A terminal event censors a non-terminal
event, but not the vice versa. Data that contain both terminal and non-terminal
events are referred to as semi-competing risks data (Fine, Jiang and Chappell [33]).
Semi-competing risks data are outside the scope of this dissertation.

2.2

The Latent Failure Time

Historically, the competing risks model is formulated via latent failure times
T1 , . . . , TK corresponding to each cause of event (Berman [9], Cox [21], Gail [34],
Moeschberger and David [69]). Each Tj , j = 1, . . . , K, is a non-negative continuous
random variable. The observed T and C are defined as T = min(T1 , . . . , TK ) and
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C = {j : Tj ≤ Tk , k = 1, . . . , K}. The joint survival function for T1 , . . . , TK is
defined as

Ḡ(t1 , . . . , tK ) = P (T1 > t1 , . . . , TK > tK ).

(2.2.1)

There have been two different conceptual interpretations on the latent failure
times. One approach (Cox [21], Moeschberger and David [69]) defines Tj to be the
event time of cause j that would be observed if all other risks were removed. This
approach of interpretation relies on the assumption that the event time of cause j is
not affected by the presence of other risks. This assumption may hold in reliability
studies in which each component of the system is physically, functionally, and statistically independent of one another. However, in general cases, this assumption is too
strong since the presence or the removal of one risk may well change the effects of
other risks (Cornfield [20], Makeham [65]). The other approach (Gail [34]) assumes
the existence of T1 , . . . , TK on each subject under the actual study conditions. Any
interrelationship among the risks is expressed in terms of the joint survival function
Ḡ. Independence between risks j and k is translated into the statistical independence of Tj and Tk . The survival function of Tj , Ḡj (t), given the removal of all
other risks, is defined to be the marginal survival function of Tj . If all risks are
independent with one another, the joint survival function and the marginal survival
functions have the following relationship

Ḡ(t1 , . . . , tK ) =

K
Y
j=1

and the survival function for T is given by

Ḡj (tj ),

(2.2.2)
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S(t) =

K
Y

Ḡj (t).

(2.2.3)

j=1

The estimation of the marginal distributions of T1 , . . . , TK used to be the main
objective of competing risks analysis. Unfortunately, given only the observed data
(T, C) and without any additional assumptions, one can never obtain exact information on the marginal distributions of individual event times or the dependence
structure among them. It is well-known fact that, for any joint survival function
with an arbitrary dependence structure among the causes of the event, one can find
a different joint survival function with independent failure time distributions, such
that the two models have the same cause-specific hazard functions (Cox [21], Crowder [22], Tsiatis [92]). This means that neither the joint survival function Ḡ nor the
marginal survival functions Ḡj , j = 1, . . . , K, is identifiable. And it is not possible
to test the independence of the marginal failure times. To identify these quantities,
one has to make an a priori assumption on the dependence among the marginal
failure times through, for example, a copula. Zheng and Klein [111] showed that the
marginal distributions can be identified if the copula function is known. It is also
possible to achieve identifiability in the cases of discrete failure times, regression
models and parametric models. A detailed survey on this topic can be found in
Crowder [23].

2.3

The Cause-Specific Hazard

The cause-specific hazard function due to cause j (Altshuler [3], Chiang [17, 18],
Holt [44], Prentice and Breslow [79], Prentice et al. [80]) is defined as
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P (t < T ≤ t + ∆t, C = j|T ≥ t)
.
∆t→0
∆t

λj (t) = lim

(2.3.1)

The function λj (t)∆(t) is the conditional probability that the event occurs from
cause j at time t given that the event has not occurred up to time t. It is also
referred to as the instantaneous failure rate from cause j at time t in the presence of
other competing risks. The overall hazard function and the overall survival function
can be expressed in terms of the cause-specific functions as

λ(t) =

K
X

λj (t)

(2.3.2)

j=1

and
( K Z
)
 Z t

X t
S(t) = exp −
λ(u)du = exp −
λj (u)du .
0

j=1

(2.3.3)

0

Suppose we observe a set of data (ti , ji , δi ), i = 1, . . . , n, from n subjects, where ti
is the observed event time, ji is the cause of the event, and δi is a censoring indicator
which takes one if the event occurs and zero otherwise. We only consider right
censoring. Then, under the assumption of independent censoring, the likelihood
function of the data is proportional to
 Z
K
n
n
Y
Y
Y
δi
δi
exp −
[λji (ti )] S(ti ) =
[λji (ti )]
i=1

i=1

j=1

0

ti



λj (u)du .

(2.3.4)

It can be seen that the above likelihood function is completely specified in terms of
the cause-specific function λj (t), j = 1, . . . , K. Furthermore, the likelihood function
can be factored into K separate components as
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 Z
n
K Y
n
Y
Y
δij
δi
[λj (ti )] exp −
[λji (ti )] S(ti ) =
i=1

ti

λj (u)du ,

0

j=1 i=1



(2.3.5)

where δij equals one if ji = j and zero otherwise. Note that each component is
exactly the same as the likelihood function that would be obtained by censoring
events from all other causes. Thus, it is clear that each λj (t) is identifiable. This is
the basis of the cause-specific hazard approach to the competing risks data proposed
by Kalbfleisch and Prentice [50] and Prentice et al. [80]. Since the cause-specific
approach treats events from other causes as censored when studying a certain cause,
all standard methods in the regular survival analysis can be applied. It also needs
to be mentioned that the cause-specific approach makes no assumption on the interrelationships among the different causes of the event.

2.4

The Cumulative Incidence Function

The cumulative incidence function (CIF) for cause j is defined as

Fj (t) = P (T ≤ t, C = j)

(2.4.1)

and can be expressed in terms of the cause-specific functions as

Fj (t) =

Z

t

λj (u)S(u)du.

(2.4.2)

0

It is also known as the subdistribution function and represents the cumulative probability of observing an event from cause j in presence of competing risks without
any assumption on the dependence among the risks. Its limiting value
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pj = lim Fj (t) = P (C = j)
t→∞

(2.4.3)

is the eventual probability of observing an event from cause j. The overall survival
function can be written in terms of the cumulative incidence functions as

S(t) = 1 −

K
X

Fj (t).

(2.4.4)

j=1

Therefore, the likelihood function derived in the last section can also be completely
specified by the cumulative incidence functions. If there is only one risk in the system, the cumulative incidence function is identical to a regular cumulative distribution function. When there are competing risks, each cumulative incidence function
is an improper distribution function. A distribution (or survival) function F (t) (or
S(t)) is said to be proper if limt→∞ F (t) = 1 (or limt→∞ S(t) = 0) and improper
otherwise. Note that the cumulative incidence functions are clearly identifiable.
Historically, the cumulative incidence functions were considered a secondary information source to the overall survival function (Benichou and Gail [7], Gaynor
et al. [35], Korn and Dorey [55]). In recent years, however, there has been growing interest in these quantities which are frequently presented in medical articles.
Medical investigators are interested in studying the event-specific failure probabilities and comparing the difference in the cumulative incidence rates among different
events. In addition, it is of interest to determine the treatment effect and to identify
prognostic factors for a particular type of failure in presence of competing risks.
Furthermore, a graphical plot of the cumulative incidence function is more intuitive
and appealing than a plot of hazard function. As a result, the cumulative incidence
function has been essential to decision making (Pepe and Mori [76]). While it is
possible to estimate the cumulative incidence function from the cause-specific haz-
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ard function via (2.4.2), this is usually analytically intractable and does not yield
an explicit form of expression. The resulting cumulative incidence function is highly
nonlinear in the covariates and are difficult to interpret. Furthermore, it has been
shown that the effect of a covariate on the cause-specific hazard function can be significantly different from its effect on the cumulative incidence function (Gray [40],
Pepe [75]). It is even possible for a covariate that has very strong influence on the
cause-specific hazard function to have no effect on the cumulative incidence function. Thus, the cause-specific hazard approach is insufficient for making inference
on the cumulative incidence functions. Methods that directly model the cumulative
incidence functions are highly desirable.
Before we move on to discuss the estimation of cumulative incidence functions,
there are several probabilistic quantities that need to be clarified. Let λj (t) be the
cause-specific hazard function for cause j. The quantity
 Z t

Sj (t) = exp −
λj (u)du

(2.4.5)

0

defines a mathematically proper survival function. It is sometimes called the causespecific survival function. However, it is not the survival function for any observable
random variable. In particular, it should not be interpreted as the marginal survival
function. It only has this interpretation when the causes are independent. From
(2.3.3), the overall survival function is the product of these cause-specific survival
functions:

S(t) =

K
Y
j=1

Sj (t).

(2.4.6)
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One can obtain a Kaplan-Meier estimator Ŝj (t) of Sj (t) by censoring events from
other causes. But one cannot use 1 − Ŝj (t) to estimate Fj (t). Note that

1 − Sj (t) =

Z

t

λj (u)Sj (u)du ≥
0

Z

t

λj (u)S(u)du = Fj (t),

(2.4.7)

0

where the equality occurs only if there is no competing risk. Thus, the KaplanMeier estimator of Fj (t) is upwardly biased. The underlying reason for this bias is
that causes may not be independent and that, when events from other causes are
treated as censored events, the censoring times and the event times are no longer
independent. A subject who is censored due to an event from other causes will not
experience the event due to the cause of interest with probability one. A detailed
explanation of this issue can be found in Gooley, Leisenring, Crowley and Storer
[38] and Putter, Fiocoo and Geskus [81].
One important probability function is Sj∗ (t) = 1 − Fj (t). This is an improper
survival function since limt→∞ Sj∗ (t) = 1 − limt→∞ Fj (t) = 1 − P (C = j) is strictly
positive if there are at least two distinct causes of the event. Sj∗ (t) represents the
probability of not experiencing the event from cause j before time t. This probability
is used to build the semiparametric regression model for the cumulative incidence
function (Fine and Gray [32]) and will also be the basis of our proposed model. Note
that Sj∗ (t) should not be confused with S̃j (t) = P (T > t, C = j) = P (C = j)−Fj (t),
which represents the probability of experiencing the event from cause j after time
t. The overall survival function can be written as the sum of S̃j (t), j = 1, . . . , K, as

S(t) =

K
X
j=1

S̃j (t).

(2.4.8)
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It can be seen that Sj (t), Sj∗ (t) and S̃j (t) are three different probabilistic quantities
with respective interpretations. Although each of them can be independently identified from the data, they are often not of direct interest in practical applications.
A detailed explanation of these three functions can be found in Porta, Gomez, Calle
and Malats [78].

2.4.1

Nonparametric Estimators

Let 0 < t1 < · · · < tN be the ordered distinct event times from any cause. Let
djl denote the number of subjects experiencing the event due to cause j at time tl
P
and dl = K
j=1 djl be the total number events at time tl . Let nl be the number of

subjects at risk (i.e. subjects who have not experienced any event or censored) at
time tl . The Kaplan-Meier estimator of the overall survival function is thus given

by

Y
dl
1−
Ŝ(t) =
.
nl
l:t ≤t

(2.4.9)

l

Next, consider a discretized version of the cause-specific hazard function (2.3.1):

λj (tl ) = P (T = tl , C = j|T > tl−1 ).

(2.4.10)

This quantity can be estimated by

λ̂j (tl ) =

djl
.
nl

(2.4.11)

Then the Kaplan-Meier estimator of the overall survival function can be written as
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Ŝ(t) =

Y

1−

l:tl ≤t

K
X

!

λ̂j (tl ) .

j=1

(2.4.12)

Since the unconditional probability of experiencing the event from cause j at time
tl can be estimated by P̂ (T = tl , C = j) = λ̂j (tl )Ŝ(tl−1 ), a natural nonparametric
estimator of Fj (t) is given by

F̂j (t) =

Z

t

λ̂j (u)Ŝ(u)du =

0

X

λ̂j (tl )Ŝ(tl−1 ).

(2.4.13)

l:tl ≤t

This is indeed the nonparemetric maximum likelihood estimator of Fj (t) (Aalen [1],
Kalbfleisch and Prentice [50]). This estimator is valid regardless of whether or not
there are ties in the event times. For interval-censored or truncated competing risks
data, the nonparametric maximum likelihood estimator for the cumulative incidence
functions is given in Hudgens, Satten and Longini [46]. Gray [40] developed a logrank type of test for nonparametric comparison of equality of cumulative incidence
functions. The method can be used to test the effect of a discrete covariate on the
cumulative incidence functions, although it cannot quantify that effect.

2.4.2

Semiparametric Models

Fine and Gray [32] adapted the Cox proportional hazard model to the cumulative
incidence function and introduced a semiparametric model that directly regresses
on the cumulative incidence function. The hazard function corresponding to the
cumulative incidence function Fj (t) can be defined as

14

1
P (t < T ≤ t + ∆t, C = j|T ≥ t ∪ (T < t ∩ C 6= j))
∆t
d log[1 − Fj (t)]
= −
.
(2.4.14)
dt

hj (t) =

lim

∆t→0

It can be thought of as the hazard function for the improper random variable Tj∗
such that Tj∗ = I(C = j) × T + I(C 6= j) × ∞. Gray [40] used this function to
construct the nonparametric test of equality of the cumulative incidence functions.
From the definition of hj (t), subjects who experience the event from any other cause
will remain in the risk set forever. This is distinct from that of the cause-specific
hazard function, whose risk set decreases each time an event occurs. Fine and Gray
[32] imposed a proportional hazard model on each hj (t), j = 1, . . . , K, as

hj (t|Z) = hj0 (t) exp(βj′ Z),

(2.4.15)

where hj0 (t) is an unspecified, non-negative, and increasing function in t. When
data are complete (i.e. the event and the cause are observed for all subjects),
the estimation follows the usual partial likelihood approach for the standard Cox
model except that one needs to account for a different risk set. When there is right
censoring, the inverse probability of censoring weighting (IPCW) method (Robins
and Rotnitzky [82]) can be adapted to construct unbiased estimating equations
from the score functions of the complete-data partial likelihood. Fine and Gray [32]
also showed that the IPCW method can be generalized to allow the dependence of
censoring times on the covariates.
There have been extensions on the framework of Fine and Gray [32]. Fine [31]
considered a transformation model on Fj (t) as
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g[Fj (t|Z)] = hj0 (t) − βj′ Z,

(2.4.16)

where g(·) is a known differentiable function and hj0 (t) is an unspecified, nonnegative, invertible, and strictly increasing function in t. The model considered
by Fine and Gray [32] is a special case with g(x) = log(− log(1 − x)). Klein and
Anderson [54] proposed a method that utilizes the pseudovalues derived from the
jackknife estimate of the cumulative incidence function to estimate the regression
parameters. Klein [53] furthered this idea to construct an additive model on the
cumulative incidence function. Scheike [86] developed a binomial regression model
on the counting process associated with each cause of the event.

2.4.3

Parametric Models

Jeong and Fine [48] proposed a direct approach of modeling the cumulative
incidence function with the Gompertz distribution with parameters α and β whose
distribution function and hazard function are

F (t|α, β) = 1 − exp[β{1 − exp(αt)}/α]

(2.4.17)

h(t|α, β) = β exp(αt)

(2.4.18)

and

respectively. Its hazard function is either increasing or decreasing. When α < 0 and
|β| < ∞, the Gompertz distribution is improper in the sense that limt→∞ F (t|α, β) <
1. This feature is shared with the cumulative incidence function and makes the
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Gompertz distribution a potential candidate for directly modeling the cumulative
incidence function. Jeong and Fine [48] used the Gompertz distribution to model
the cumulative incidence function of each cause and developed maximum likelihood
estimates. Jeong and Fine [49] further integrated this idea into the transformation
model (2.4.16) of Fine [31]. They let

gj [Fj (t|Z)] = log[{(1 − Fj (t|Z))−aj − 1}/aj ], −∞ < aj < ∞,

(2.4.19)

which reduces to the proportional hazard model when aj → 0 and the proportional
odds model when a = 1. They then constructed a regression model as

gj [Fj (t|Z)] = hj0 (t) + βj′ Z.

(2.4.20)

To account for the fact that Fj (t) is improper, they used the Gompertz distribution
to parametrize the hj0 (t). The maximum likelihood estimates and the corresponding
large sample inferences can be applied on each parameter.
Another model worth mentioning is the mixture model considered by Larson and
Dinse [58] and Maller and Zhou [66, 67]. They formulated the Fj (t) as

Fj (t) = P (T ≤ t, C = j) = P (T ≤ t|C = j)P (C = j).

(2.4.21)

Note that 1 − P (T ≤ t|C = j) is the cause-specific survival function (2.4.5) and can
be modeled either using the cause-specific hazard approach or directly by a parametric or semiparametric model. The probability P (C = j), which equals Fj (∞),
can be modeled by a multinomial regression model if each subject will eventually
experience the event due to one cause. Jeong and Fine [48] reported that, while
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their model yielded a lower AIC, the estimated cumulative incidence functions from
their model are almost identical to those from the above formulation.

2.5

Discussion

Parametric and semiparametric models have their own advantages and disadvantages. The parametric model enables the estimation of the long-term probability of
experiencing the event due a specific cause in the presence of competing risks, a quantity that is often of great interest to scientific investigators. Plots from a parametric
analysis are smoother and often have better graphical display than those obtained
from a nonparametric or semiparametric analysis. It is also easier to accommodate
different censoring and truncation schemes and to conduct Bayesian analysis in a
parametric model. Furthermore, the parametric estimators are often more efficient
than the nonparametric and semiparametric ones. However, parametric models rely
on distributional assumptions that are difficult to verify and may produce biased
estimates due to misspecification. Besides, the parameters in a parametric model
can be difficult to interpret.
One issue with the semiparametric and parametric models reviewed so far is that
P
the sum of the cumulative incidence functions may exceed one, i.e., K
j=1 lim Fj (t) >
t→∞

1. Jeong and Fine [48] noticed that their model might result in an overall survival
P
function which is strictly less than one, i.e., K
j=1 lim Fj (t) < 1. If this happens,
t→∞

one may conclude that a fraction of the subjects are immune to all causes of the
event, although this is usually contrary to the reality. However, the problem is more
serious if the overall survival function is greater than one. Lin [61] gave a real data
example where this actually happens. Jeong and Fine [48] discussed the possibility
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of enforcing the overall survival function to be proper and remarked that this would
greatly complicate the analysis.
There are several other open research areas on the regression models of the
cumulative incidence function. For example, it is often of interest to test the equality
of the covariate effects across different causes of the event, but the existing models do
not yet have this capability. It is also common to observe time-varying covariates in
real studies, and how to incorporate them in the modeling is still an ongoing research
topic. Another important issue is the goodness-of-fit of the model. So far there has
been no statistical test available for that. One convenient method adopted by most,
if not all, researchers (Fine and Grey [32], Jeong and Fine [48], Putter et al. [81])
is to compare the estimates from fitted model with the nonparametric estimates.

CHAPTER 3
CURE MODELS

3.1

Introduction

The cure models are developed to model the survival data where a fraction
of subjects will never experience the event. Such subjects are considered to be
cured and this fraction is referred to as the cure rate. Generally, cure cannot be
observed directly but can be inferred from a survival curve levelling off at a strictly
positive value after a sufficient follow-up period. Occasionally, the criteria of cure
is predefined and cured subjects can thus be identified. In such cases, estimation
of the cure rate and the survival function follows the regular method. When cure
is not observed, a new class of models is needed to model the data. There are two
main classes of cure models. One is the mixture cure model proposed by Berkson
and Gage [8]. The other is the bounded cumulative hazard model formulated by
Yakovlev et al. [99] and Yakovlev and Tsodikov [100]. Most of the existing cure
models are based on these two frameworks or their variations.

3.2

Mixture Cure Model

The mixture cure model was first proposed by Berkson and Gage [8]. The model
assumes that a fraction c, which is known as the cure rate, of the population is
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cured and the remaining 1 − c is still susceptible to the event with a proper survival
function S0 (t). The overall survival function for the entire population is given by

S(t) = c + (1 − c)S0 (t).

(3.2.1)

Note that limt→∞ S(t) = c > 0. Thus, the overall survival function is improper and
cannot be described by a regular survival model.
The mixture cure model has the advantage that it enables separate modeling of
the cure rate c and the survival function S0 (t). The cure rate c can be linked with
the covariates through a binomial regression model, such as the logistic model, the
probit model, the complementary log-log model and etc. The survival function S0 (t)
can be formulated by any regular survival model, including the Cox model and the
accelerated failure time model. It is possible that c and S0 (t) depend on the same
covariate(s). The effects of the same covariate(s) on the cure rate and the survival
function can be separately interpreted. However, the computation of the maximum
likelihood estimates of the mixture cure model can be difficult. Kuk and Chen
[56] developed a Monte Carlo simulation-based algorithm for maximum likelihood
estimation. Sy and Taylor [88] considered a semiparametric EM algorithm. Lu
[62, 63] studied nonparametric maximum likelihood estimation method for the Cox
and accelerated failure time model with a cure fraction. Chen, Ibrahim and Sinha
[14] showed that the mixture cure model yields an improper posterior distribution if
an improper flat prior distribution is used on the regression parameters of the cure
rate.
There has been extensive research on the mixture cure model, including Fang,
Li and Sun [27], Farewell [28, 29], Goldman [37], Kuk and Chen [56], Li and Taylor
[59], Lu [62, 63], Lu and Ying [64], Peng, Dear and Denham [72], Peng and Dear
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[73], Sy and Taylor [88], Taylor [89], Yamaguchi [102], Zhang and Peng [110], and
many others.

3.3

Bounded Cumulative Hazard Model

The bounded cumulative hazard model was formulated by Yakovlev et al. [99]
and Yakovlev and Tsodikov [100] based on characteristics of tumor growth. The
bounded cumulative hazard model takes the form

S(t) = exp{−θF (t)},

(3.3.1)

where θ > 0 and F (t) is the distribution function of some nonnegative random
variable. It is easy to see mathematically that limt→∞ S(t) = exp(−θ) > 0. Thus,
S(t) is an improper survival function and could be a potential candidate for modeling
survival data with a cure fraction, which is given by exp(−θ). The cumulative hazard
function corresponding to S(t) is θF (t), which is bounded from above, hence the
name of the model. However, Yakovlev et al. [99] developed the model from purely
biological considerations. A more direct and easily understood motivation is given
by Chen et al. [14]. They assumed that for each individual there are N metastatic
competent tumor cells and that each cell has a latent incubation time Zj . The
event is observed if any one of the cells is activated. Then, under the following
assumptions:
(1) N follows a Poisson distribution with mean θ
(2) Zj , j = 1, 2, . . . , are independently and identically distributed with a common
distribution function F (t)
(3) N is independent of Zj ’s,
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the survival function for the event time exactly has the form (3.3.1). Note that the
bounded cumulative hazard model can be written in the form of a mixture cure
model as

S(t) = e−θ + (1 − e−θ ) ×

e−θF (t) − e−θ
.
1 − e−θ

(3.3.2)

Chen et al. [14] considered a regression model on θ through θi = exp(x′i β), which
results in a proportional hazard model, and proved the propriety of the posterior
distribution under some general conditions for the use of flat prior on β. Tsodikov,
Ibrahim and Yakovlev [94] conducted a detailed review on the bounded cumulative
hazard model and its comparison with the mixture cure model. They considered a
richer class of nonlinear transformation regression models to describe the covariate
effects. They concluded that the bounded cumulative hazard model has certain technical advantages over the mixture cure model in maximum likelihood and Bayesian
estimation procedures. However, it is more difficult to interpret the effect of a covariate in the bounded cumulative hazard model. It can be seen from (3.3.2) that
the survival function for the uncured population is a highly nonlinear function of θ.
Thus, if a regression model is built through θ, the effect of a covariate on the survival function is hard to assess. Besides, one may also be interested in constructing
a regression on F (t) as well, which could possibly depend on the same covariates
and make the interpretation even harder.
There are several extensions on the bounded cumulative hazard model. Gu,
Sinha and Banerjee [41] followed the framework of Chen et al. [14] but instead
assumed a geometric distribution on N with probability density function P (N =
k) = θk /(θ + 1)k+1, k = 0, 1, 2, . . . . The resulting survival function for the entire
population is
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S(t) =

1
.
1 + θF (t)

(3.3.3)

The cure rate is given by 1/(1 + θ). When a regression model is built through θ, the
above survival function will have a proportional odds structure. Of course, other
choices of probability distribution for N is possible. Cancho, Castro and Dey [11]
considered a power series distribution with mass function

P (N = n|θ) =
where A(θ) =
form

P∞

n=0 cn θ

n

cn θ n
, n = 0, 1, 2, . . . ,
A(θ)

(3.3.4)

, θ > 0, cn ≥ 0. The population survival function takes the

S(t) =

A(θ[1 − S(t)])
.
A(θ)

(3.3.5)

The power series distribution includes as special cases many commonly used distributions, such as Poisson, geometric, binomial, negative binomial, etc. Thus, the
above model also includes as special cases the proportional hazard model of Chen
et al. [14] and the proportional odds model of Gu et al. [41].
Cooner, Banerjee, Carlin and Sinha [19] extended the framework of Chen et al.
[14] by introducing another latent factor, r, which can be either fixed or random,
as the threshold for the event to be observed. That is, the event is observed if r of
the N latent factors are activated. If r = 1, the model reduces to that of Chen et
al. [14] or Gu et al. [41] and is called the first-activation model. When r = N, the
model is called the last-activation model. In general, the model has a hierarchical
activation scheme in which r can be assigned a probability distribution defined on
integers 0, 1, . . . , N. Kim, Chen and Dey [51] considered a different latent activation
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scheme. They assumed that there is a latent variable R that represents the number of
latent factors acting in the opposite direction of the activation factors. For example,
if N is the number of tumor cells, then R could be the number of antibodies. The
subject is cured if R > N. Otherwise, the event time will be the Rth-order statistic
of the incubation times of the tumor cells.

3.4

Transformation Models

Yin and Ibrahim [105] applied the Box-Cox transformation on the population
survival function and derived a class of transformation models of the form
S(t)a − 1
= −θ(a)F (t), a ∈ [0, 1].
a

(3.4.1)

The overall survival function is then written as

S(t) = [1 − aθ(a)F (t)]1/a .

(3.4.2)

The cure rate is given by (1 − aθ)1/a . This class of models includes as special cases
the mixture cure model (a = 1) and the bounded cumulative hazard model (a = 0).
Although the parameter a can theoretically take any value on the positive real line,
they focused on their interest on [0,1] as the resulting model is kind of “intermediate”
between the two popular cure models. A regression model can be built through θ as

θi (a, xi ) =

exp(x′i β)
.
1 + a exp(x′i β)

(3.4.3)

It can be seen that this also reduces to the bounded cumulative hazard regression
model of Chen et al. [14] when a = 0 and to the logistic regression model in the
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mixture cure model when a = 1. Peng and Xu [74] showed that this class of transformation models can be derived from the bounded cumulative hazard framework
of Chen et al. [14] by assuming N to be a binomial variate. They also extended the
parameter space of a from [0,1] to [0,∞) and discussed the likelihood ratio test and
the score test for testing the adequacy of the mixture cure model and the bounded
cumulative hazard model. Smith [87] and Taylor and Liu [90] considered a different
transformation:
cλ − 1
S(t)λ − 1
=
F (t),
λ
λ

(3.4.4)

where c is the cure rate and λ ∈ (−∞, ∞) is the transformation parameter. When
λ = 0, the model reduces to the bounded cumulative hazard model, and when λ = 1,
it reduces to the mixture cure model.
Zeng, Yin and Ibrahim [109] proposed a class of semiparametric transformation
models of the form

S(t) = Gγ {θF (t)},

(3.4.5)

where Gγ (·) is the transformation function. If

Gγ (x) =



 (1 + γx)−1/γ ,

 e−x ,

γ>0
γ = 0,

then this transformation model reduces to the proportional hazard model of Chen
et al. [14] for γ = 0 and to the proportional odds model of Gu et al. [41] for γ = 1.
Other transformation can be also be considered. For example, let
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 exp{− (1+x)γ −1 },
γ
Gγ (x) =

 1 ,
1+x

γ>0
γ = 0.

Then the proportional hazard model is obtained when γ = 1 and the proportional
odds model corresponds to γ = 0. Note that F (t) can be modeled in various
ways. Zeng et al. [109] modeled it nonparametrically. Thus, one needs to assume
a priori a cut-off follow-up period so that subjects who survive longer than that
period are considered to be cured. Under this assumption, Zeng et al. [109] derived
nonparametric maximum likelihood estimates and their asymptotic properties.
These transformation models offer more flexibility to analyze the overall survival
curve and the covariate effects. However, they also suffer from the disadvantage that
the regression as well as the transformation parameters become much more difficult
to interpret.

3.5

Joint Models for Cure Rate and Correlated Data

Many medical investigations will generate dependent data as well as survival
data. Joint modeling of such data has become essential. In general, the dependent
data arise in two situations. In the first one, longitudinal measurements are taken
from an individual and result in a dependent stochastic process. For example, it
is common to have a repeatedly measured biomarker outcome which is an important indicator of disease progression. In such cases, modeling the event time using
biomarker observations as time-dependent covariates in a traditional Cox proportional hazard model is often difficult, since the regular Cox model requires that the
values of the time-dependent biomaker are known for all subjects at all failure times.
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To address this issue, two types of models for both longitudinal and survival data
have been proposed. The two-stage approach (Bycott and Taylor [10], Dafni and
Tsiastis [24], Tsiatis, DeGruttola and Wulfsohn [93]) uses a separate model for the
biomarker process to predict its values at each failure time and then plugs them in
the regular Cox model. The likelihood-based approach (Faucett and Thomas [30],
Henderson, Diggle and Dobson [43], Wang and Taylor [95], Wulfsohn and Tsiatis
[96], Xu and Zeger [98]) jointly models the biomarker process and the time-to-event
process based on the full likelihood. Both approaches can be extended to accommodate a cure fraction. Yu, Law, Taylor and Sandler [108] adopted the mixture cure
formulation and Chen, Ibrahim and Sinha [16] used the bounded cumulative hazard
model.
In the other situation, the population consists of several clusters. The responses,
which include the cure status and the survival time, from subjects within the same
cluster are naturally correlated. Sometimes, each individual is a cluster, such as
the case when the relapse time and the survival time of the individual are jointly
modeled. There have been wide extensions of the cure model to accommodate such
correlations. Chatterjee and Shih [12] used the copula to account for the association
in a bivariate model. Chen, Ibrahim and Sinha [15] extended their bounded cumulative hazard model to accommodate dependent data with frailties. Banerjee and
Carlin [5] developed a cure model for interval-censored spatial data. Lai and Yau
[57] and Yu and Peng [106] extended the mixture cure model to correlated data. The
former used the marginal approach and the latter used the random effects model.
Xiang, Ma and Yau [97] further extended the latter model for interval-censored
data. Moger and Aalen [70, 71] proposed a frailty model that uses a single frailty to
account for both the cure fraction and the dependence among survival times for the
uncured subjects. A smaller value of the frailty parameter indicates a higher cure
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probability and a longer survival time. This is often consistent with the common
sense that a subject with a low chance of cure rate is also likely to have an earlier
event time (Kim and Jhun [52]).

3.6

Cure Rate in Presence of Competing Risks

Basu and Tiwari [6] and Sarkar [85] developed competing risks cure models to
accommodate the fact that, in presence of competing risks, subjects may be cured
from some risks but will eventually experience the event from one of the other risks.
Both of them used the cause-specific hazard approach to model the competing risks.
Basu and Tiwari [6] considered the mixture cure model and Sarkar [85] adopted
the bounded cumulative hazard model to account for the cure rate. To illustrate,
suppose there are two competing risks and the first risk can be cured. Let Λ1 (t)
and Λ2 (t) be the cause-specific cumulative hazard function of the two risks for the
entire population respectively. Let Λ1 (t)∗ be the cause-specific cumulative hazard
function of the first risk for the uncured population. Let c1 be the cure rate of the
first risk. The mixture cure model yields an overall survival function of the form

S(t) = c1 × exp[−Λ2 (t)] + (1 − c1 ) × exp[−Λ1 (t)∗ − Λ2 (t)],

(3.6.1)

where both Λ1 (t)∗ and Λ2 (t) are proper cumulative hazard functions. The bounded
cumulative hazard formulation results in an overall survival function:

S(t) = exp[−Λ1 (t) − Λ2 (t)] = exp[−θF (t) − Λ2 (t)],

(3.6.2)
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where θ > 0 and F (t) is the proper distribution function of some nonnegative random
variable. Note that Λ1 (t) is an improper cumulative hazard function. The cure rate
c1 is given by exp(−θ). Both (3.6.1) and (3.6.2) are proper survival functions and
will give a better representation of the overall survival curve than the ones which
ignore either the cure rate or the competing risks.
A key issue of the above two models is the interpretation of the cure rate c1 .
Note that c1 is the limit of the cause-specific survival function
 Z
c1 = lim S1 (t) = lim exp[−Λ1 (t)] = exp −
t→∞

t→∞

∞
0


λ1 (t)dt .

(3.6.3)

Therefore, it is not the marginal cure rate of the first risk. The marginal cure rate
equals

c∗1 = lim Ḡ1 (t),
t→∞

(3.6.4)

where Ḡ1 (t) is the marginal survival function of the first risk as defined in Section
2.2. In fact, any marginal cure rate in presence of competing risks is not identifiable
in general, per the discussion in the previous chapter. We will call c1 the causespecific cure rate. It will be the same as the marginal cure rate if all competing
risks are independent. It is also worth mentioning that these two competing risks
cure models are both equivalent to fitting two separate models on the two risks, one
with a cure model and the other with a regular survival model.

CHAPTER 4
A NEW CLASS OF FLEXIBLE CURE MODELS

4.1

Introduction

The mixture cure model (Berkson and Gage [8]) assumes that a fraction of the
patients are cured from disease and will never experience the event (death or incidence) from the disease. This model has been extensively studied in the literature.
Chen et al. [14] proposed an alternative cure rate model based on a model of metastasis mechanism proposed by Yakovlev et al. [99] and Yakovlev and Tsodikov [100].
This model is based on an unknown number, N ≥ 0, of latent biological factors
present in the patient that contribute to the event (such as mortality or recurrence)
of interest. The case of N = 0, that is, when none of these contributing factors is
present in the patient, provides the possibility of cure in this model. For N > 0, the
activation times Y1 , . . . , YN for the N latent factors are assumed to be i.i.d. with a
common distribution F (t). In the cancer recurrence model of Yakovlev et al. [99], N
is the number of metastasis-competent cells (clonogens) that are in an irreversible
process toward metastasis, and Yk , k = 1, . . . , N, is the time needed for the k th
clonogen to produce a “detectable” tumor.
In the original development of this model in Chen et al. [14] and Yakovlev et
al. [99], the patient-level event, such as cancer recurrence, happens as soon as any
one of the latent factors activates (for example, any one clonogen metastasizes),
leading to the well-known competing risks-type structure for time to patient-level
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event T0 as T0 |N = min{Y1 , . . . , YN } and S0 (t|N) = P (T0 ≥ t|N) = I{N = 0} +
[1 − F (t)]N I{N ≥ 1}, where I{·} denotes the indicator function. Cooner et al.
[19] refered to this as the first-activation model. Chen et al. [14] and Yakovlev
et al. [99] considered the case when N ∼ Poisson(θ), in which case the marginal
distribution of T0 is given by the well-known form S0 (t) = exp(−θF (t)) and cure
fraction c = lim S0 (t) = exp(−θ) = P (N = 0).
t→∞

The first-activation model is based on the concept of a latent series system with
unknown number of N components where failure of any one component due to the
activation of the latent risk initiates the patient-level event. An alternative model
is that of a latent parallel system where the system continues to function as long as
at least one component is functioning and the patient-level event is initiated only
when all latent risks are activated. This leads to what Cooner et al. [19] termed
as the last-activation model where T1 |N = max{Y1 , . . . , YN } and S1 (t|N) = I{N =
0} + {1 − F (t)N } I{N ≥ 1}. The marginal survival function for the case when N ∼
Poisson(θ) is given by S1 (t) = 1 + exp(−θ) [1 − exp(θ F (t))] with associated cure
rate c = lim S1 (t) = exp(−θ) = P (N = 0). Since both of these models are based
t→∞

on latent structures, the question then arises on how to choose between these two
models for analysis of a specific dataset.
In this chapter, we propose a class of cure rate models indexed by a parameter
a on the continuum. The first-activation and the last-activation models are two
points on this model space continuum corresponding to the cases of a = 0 and a = 1
respectively. Further, in Theorem 4.2.2, we establish that our proposed survival
function Sa (t) of Ta is, in fact, stochastically ordered in terms of a. This implies
that the first-activation and the last-activation models are stochastically ordered
S0 (t) ≤ S1 (t), ∀t ≥ 0. Moreover, the continuum of models {Sa (t) : 0 < a < 1}
spans the space in between these two.
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Another strong feature of this class of models is that the survival function Sa (t)
has a closed-form expression that is analytically tractable. Cooner et al. [19], for
example, proposed the hierarchical activation model based on the intermediate order
statistics Y(r) , 1 ≤ r ≤ n, which fall in between the minimum Y(1) and maximum
Y(N ) of the first- and last-activation models. However, the expression of the marginal
survival function for this general order statistic model involved expectation of an
incomplete Beta function. As a consequence of this intractability, the analysis of
this model almost invariably involves invoking the latent structure that may induce
computational issues in the Markov chain sampler. In contrast, the model proposed
here provides a closed-form and tractable expression for Sa (t).
Model identifiability has been a topic of intense research in minimum-type competing risks models. Li, Taylor and Sy [60] examined the identifiability of the
first-activation model. We establish in Section 4.3 that even though we propose a
class of cure rate models indexed by a, these models are identifiable under parametric assumptions or regression structures. These results provide strong foundational
support of data analysis with this model.

4.2

4.2.1

A General Class of Cure Models

The Model

Let T be the event time and let x and z be two covariate vectors. Let a > 0. We
propose a model for the survival function of T of the form
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1
A
Sa (t|x, z) =
A(θ(x))




1 −1
A [c0 + A(aθ(x)) − A(aθ(x)F (t|z))] ,
a

(4.2.1)

where F (t) is a proper distribution function of some non-negative random variable
P
n
and A(θ) is a power series function of the form ∞
n=0 cn θ , θ > 0, cn > 0, such that
it is a continuous, strictly increasing and one-to-one function in θ with a unique

inverse A−1 . Since both A(θ) and F (t) are non-decreasing functions, it is easy to
see that (4.2.1) is a non-increasing function in t. In addition, we have



1 −1
A [A(aθ(x))] = 1
a



=

1
A
lim Sa (t|x, z) =
t→0
A(θ(x))
and

1
lim Sa (t|x, z) =
A
t→∞
A(θ(x))



1 −1
A [c0 ]
a

1
c0
A(0) =
.
A(θ(x))
A(θ(x))

(4.2.2)

Therefore, the function defined by (4.2.1) is an improper survival function. The
cure rate is given by (4.2.2) and is free of the parameter a. The cure rate given by
our model coincides with that of Cancho et al. [11]. In the framework of the latent
hierarchical activation model of Cooner et al. [19], Cancho et al. [11] models N
using the family of power series distributions whose probability mass function is

P (N = n|θ) =

cn θ n
, n = 0, 1, 2, . . . .
A(θ)

(4.2.3)

Under this formulation, the cure rate is P (N = 0|θ) = c0 /A(θ) and the overall
survival functions under first activation and last activation are
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SF A (t) =

A(θS(t))
A(θ)

(4.2.4)

and

SLA (t) = 1 +

c0
A(θF (t))
−
A(θ)
A(θ)

(4.2.5)

respectively. It can be shown that these two models are also special cases of our
proposed model.
Theorem 4.2.1. Let Sa (t|x, z) be the survival function defined in (4.2.1). Then

lim Sa (t|x, z) =

a→0

A(θ(x)S(t|z))
A(θ(x))

and
Sa (t|x, z, a = 1) = 1 +

A(θ(x)F (t|z))
c0
−
.
A(θ(x))
A(θ(x))

The result is obvious for a = 1. To see what happens when a → 0, observe that
(4.2.1) can be obtained from rearranging the following equation:
A(aA−1 [Sa (t|x, z)A(θ(x))]) − c0
A(aθ(x)) − c0 A(aθ(x)F (t|z)) − c0
=
−
. (4.2.6)
a
a
a
Note that

∞
X
A(aθ) − c0
= c1 θ + lim
cn an−1 θn = c1 θ.
lim
a→0
a→0
a
n=2

Thus, let a → 0 and (4.2.6) becomes
A−1 [Sa (t|x, z)A(θ(x))] = θ(x) − θ(x)F (t|z) = θ(x)S(t|z).

35
Hence, we get the first-activation model (4.2.4):

lim Sa (t|x, z) =

a→0

A(θ(x)S(t|z))
.
A(θ(x))

In the above derivation, we implicitly assume that c1 6= 0. If c1 = 0, then let cj , j > 0
be the first non-zero coefficient of A(θ) and let denominators in (4.2.6) be changed
to aj θj−1 . Therefore, the first-activation model can always be obtained.
Our model includes as special cases many existing models in the literature. In
P
θn
particular, when A(θ) = ∞
n=0 n! = exp(θ) and a = 0, it reduces to the bounded cu-

mulative hazard model. Table 4.1 shows the overall survival functions for our model
(with covariates suppressed) under first and last activation and different choices for
A(θ), along with the relevant references from the existing literature.

Table 4.1: Survival functions with different models for A(θ).
A(θ)
P∞

θj

j=0 j!

P∞

j=0

Pn

j=0

P1

j=0

P∞

= exp(θ)

θj = (1 − θ)−1
n
j

 j
θ = (1 + θ)n

1
j



θj = (1 + θ)

θj
j=0 (j!)γ

= Z(θ, γ)

a

Sa (t)

Reference

a=0
a=1
a=0
a=1
a=0
a=1
a=0
a=1
a=0
a=1

exp(−θF (t))
1 + exp(−θ) − exp(−θS(t))
−1
θ
F (t)
1 + 1−θ
−1
θ
1 + (1 − θ) − 1 + 1−θ
S(t)
n
θ
F (t)
1 − 1+θ
n
θ
1 + (1 + θ)−n − 1 − 1+θ
S(t)
θ
1
+ 1+θ
S(t)
1+θ
1
θ
+ 1+θ S(t)
1+θ

[14][99][100]

1+

Z(θS(t),γ)
Z(θ,γ)
(t),γ)
1
− Z(θF
Z(θ,γ)
Z(θ,γ)

[41]
[74][105]
[8]
[83][84]
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Note that in our model the domain of a is in general restricted such that aθ(x)
must lie in the radius of converge of A(θ). We assume that in modeling θ(x) is always
inside the radius of convergence. Therefore, for a ∈ [0, 1], aθ(x) is always inside the
radius of convergence as well. Our model has a property that it is stochastically
ordered by a, i.e., if a1 ≤ a2 and if θ and F (t) is fixed, then Sa1 (t) ≤ Sa2 (t) for
all t ≥ 0. Thus, the parameter a can be interpreted as an activation threshold.
The following theorem establishes this property. For convenience, the covariates are
suppressed in stating the theorem.
Theorem 4.2.2. Let T1 and T2 be two random variables with survival functions
Sa1 (t|a1 , θ, F, A) and Sa2 (t|a2 , θ, F, A), as defined by (4.2.1), respectively, where 0 <
a1 ≤ a2 < R/θ, and R is the radius of convergence of A(θ). Then T1 and T2 are
stochastically ordered, i.e., Sa1 (t|a1 , θ, F, A) ≤ Sa2 (t|a2 , θ, F, A) for t ≥ 0.
To prove Theorem 4.2.2, we first introduce the following lemma.
Lemma 4.2.3. Let A(y) be an absolutely convergent power series of the form

A(y) =

∞
X

cn y n ; y > 0, cn > 0, c1 > 0.

n=0

Then
y[A′′(y)]2
− yA′′′(y) − A′′ (y) 6 0.
′
A (y)
Proof. Since A′ (y) > 0, we only need to show
y[A′′ (y)]2 − yA′′′ (y)A′(y) − A′′ (y)A′(y) 6 0.
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Observe that
yA′′′ (y)A′(y) + A′′ (y)A′(y)
= (yA′′′(y) + A′′ (y))A′ (y)
=

y

∞
X

n(n − 1)(n − 2)cn y n−3 +

n=3

=

∞
X

=

n(n − 1)cn y n−2

n=2

n(n − 1)(n − 2)cn y n−2 +

n=3

∞
X

∞
X

∞
X

n(n − 1)cn y n−2

n=2

n(n − 1)2 cn y n−2

n=2

!

∞
X

!

!

!

∞
X

ncn y n−1

n=1

∞
X

ncn y n−1

n=1

!

!

ncn y n−1 .

n=1

Then, by the Cauchy-Schwarz inequality,

′′

2

y[A (y)] = y
6y
=
6

∞
X

n=2
∞
X

n(n − 1)cn y
2

n(n − 1) cn y

n=2
∞
X

2

n(n − 1) cn y

n=2
∞
X

n−2

n−2

n−2

n(n − 1)2 cn y n−2

n=2

!2
!

!
!

∞
X

ncn y

n=2
∞
X

ncn y

n=2
∞
X

n−2

n−1

!

!
!

ncn y n−1 .

n=1

Now we prove Theorem 4.2.2 as follows.
Proof. The continuity of Sa is obvious. Since A(·) is an increasing function, we only
need to prove that, given θ, F (·) and t,
1
h(a) = A−1 [c0 + A(aθ) − A(aθF (t))]
a
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is an increasing function in a, i.e., h′ (a) > 0 for any (a, θ, F (·), t).
Let x = c0 + A(aθ) − A(aθF (t)). Then
1
dx
θA′ (aθ) − θF (t)A′ (aθF (t))
d −1 ′
(A ) (x) = ′ −1
=
da
A (A (x)) da
A′ (A−1 (x))
and
1
h (a) = 2
a
′




aθA′ (aθ) − aθF (t)A′ (aθF (t))
−1
− A (x) .
A′ (A−1 (x))

Since a > 0 and A′ (A−1 (x)) > 0, we only need to show
aθ(A′ (aθ) − F (t)A′ (aθF (t))) − A−1 (x)A′ (A−1 (x)) > 0

(4.2.7)

for any (a, θ, S(·), t). This is equivalent to showing that, given a and θ, (4.2.7)
holds for any F (t) ∈ [0, 1]. Let F (t) be denoted by F and
g(F ) = aθ(A′ (aθ) − F A′ (aθF )) − A−1 (x)A′ (A−1 (x)).

Observe that when F = 0, A−1 (x) = aθ and hence g(F ) = 0; when F = 1,
A−1 (x) = 0 and hence g(F ) = 0. Since g(F ) is clearly continuous, g(F ) is guaranteed
to be non-negative if we can show all critical points of g(F ) are local maxima.
Differentiating g(F ) with respect to F yields
g ′(F ) = −aθ[A′ (aθF ) + aθF A′′ (aθF )]


aθA′′ (A−1 (x))A′ (aθF ) −1
′
A (x) − aθA (aθF )
− −
A′ (A−1 (x))
A′′ (A−1 (x))A−1 (x) ′
A (aθF ).
= −aθF A′′ (aθF ) +
A′ (A−1 (x))
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Then g ′(F = 0) = c1 aθA′′ (aθ)/A′ (aθ) > 0 and g ′(F = 1) = −aθA′′ (aθ) 6 0. Since
g ′ (F ) is also continuous, there exists some F ∗ such that g ′(F ∗ ) = 0. If we can show
that g ′′ (F ∗ ) 6 0, then the proof will be completed.
Let x∗ = c0 + A(aθ) − A(aθF ∗ ). Since g ′(F ∗ ) = 0, we have
A′′ (A−1 (x∗ ))A−1 (x∗ )
aθF ∗ A′′ (aθF ∗ )
=
.
A′ (A−1 (x∗ ))
A′ (aθF ∗ )

(4.2.8)

Some straightforward algebra shows that
A′′ (A−1 (x))A−1 (x) ′′
g ′′ (F )
= − [A′′ (aθF ) + aθF A′′′ (aθF )] +
A (aθF )
aθ
A′ (A−1 (x))
2
 ′
A (aθF )
+
A′ (A−1 (x))
 ′′ −1

[A (A (x))]2 A−1 (x)
−1
′′′
−1
′′
−1
×
− A (x)A (A (x)) − A (A (x)) .
A′ (A−1 (x))
From (4.2.8), we have
aθF ∗ [A′′ (aθF ∗ )]2
g ′′ (F ∗ )
= − [A′′ (aθF ∗ ) + aθF ∗ A′′′ (aθF ∗ )] +
aθ
A′ (aθF ∗ )
 ′
2
A (aθF ∗ )
+
A′ (A−1 (x∗ ))
 ′′ −1 ∗ 2 −1 ∗

[A (A (x ))] A (x )
−1 ∗
′′′
−1 ∗
′′
−1 ∗
×
− A (x )A (A (x )) − A (A (x )) .
A′ (A−1 (x∗ ))
Therefore, g ′′ (F ∗ ) 6 0 by Lemma 4.2.3.
A relevant result on stochastic ordering of cure rate models is stated in Kim
et al. [51], who showed that, if SLACR (t) and SF A (t) are survival functions of the
latent hierarchical activation model and the first-activation model respectively, then
SF A (t) ≤ SLACR (t) for t ≥ 0. In fact, we have SLACR (t) ≤ SLA (t) as well, where
SLA (t) is the survival function of the last-activation model.
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To build a regression model for (4.2.1), covariates can be introduced through
θ via an appropriate link function as h(θ) = x′ β. In our research, we do not do
regression on F (t).

4.2.2

A Special Case

Let A(θ) = exp(θ). Then model (4.2.1) reduces to
1

Sa (t|x) = [1 + exp(−aθ(x)) − exp(−aθ(x)S(t))] a , a 6= 0,

(4.2.9)

and
Sa (t|x) = exp(−θ(x)[1 − S(t)]), a = 0.
Since the radius of convergence of the exponential function exp(θ) is the whole real
line, in this model the parameter a can take any value on the whole real line as well.
For any a, the cure rate is limt→∞ Sa (t) = exp(−θ(x)), which is the same as the cure
rate one obtains from the bounded cumulative model. Observe that this new model
can be written as
Sa (t|x)a − 1
exp(−aθ(x)) − 1 exp(−aθ(x)S(t)) − 1
=
−
.
a
a
a
Thus, as a → 0, (4.2.9) becomes log Sa (t|x) = −θ(x)−(−θ(x)S(t)) = −θ(x)F (t), and
hence, lima→0 Sa (t|x) = exp(−θ(x)F (t)). This is exactly the bounded cumulative
hazard. And when a = 1, (4.2.9) reduces to the last-activation model.
It can be proved from Theorem 4.2.2 that, for any −∞ < a1 6 a2 < ∞,
Sa1 (t|a1 , S, θ) 6 Sa2 (t|a2 , S, θ) for t ≥ 0. As a result, we have a very flexible threshold

41
model for the failure time. The model allows the survival function Sa (t) to vary
continuously as a varies along the real line. As a increases, the hurdle for the event
to be observed grows higher. As a → ∞, Sa (t) → 1 for all t ≥ 0. This is an extreme
situation in which any subject will never experience the event. This is analogous
to the last-activation scheme with N → ∞. On the other hand, as a → −∞,
Sa (t) → exp(−θ) for all t > 0. This is another extreme case in which any non-cured
subject will experience the event immediately after time 0. This is analogous to the
first-activation scheme with N → ∞.
In the latent hierarchical activation model of Cooner et al. [19], r out of N
latent factors need to be activated for the event to occur. In our model, we can
interpret a in the same sense r is interpreted in latent hierarchical activation model.
Alternatively, a can be interpreted as a measure of the effectiveness of the antibody
produced by an immune system in preventing metastasis of tumor cells. Small values
of a suggest low effectiveness and thus result in shorter relapse, while large values of
a indicate high effectiveness and prolonged time to relapse. Theoretically, a can take
any value on the positive real line. The unrealistic limiting case is when a = ∞,
Sa (t) ≡ 1, a situation in which everyone will never fail. Thus in practice, small
values of a are more likely to be observed.
Figure 4.1 shows the survival functions for different values of a with 20% cure rate
and S(t) being the survival function of a Weibull distribution with shape parameter
1.5 and scale parameter 6. We observe that, when the cure rate exp(−θ) is not
negligible, the survival function (4.2.9) is quite close to that from the hierarchical
activation model with the distribution of r specified as r − 1|N ∼ Bin(N − 1, a).
Figures 4.2 and 4.3 illustrate the two survival functions with a variety of cure rates
and activation thresholds. The higher the cure rate, the closer the two curves are
to each other. And we see that, in the presence of a non-negligible cure fraction,
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the two survival curves are almost identical. When the cure rate tends to zero,
the difference between two curves begin to manifest and this difference grows larger
as a becomes larger. Since cure models are only applicable in situations where a
non-negligible cure fraction exists, our model clearly has an advantage since it is
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Figure 4.1: Illustration of survival function for different values of a.

To build a regression model, we can introduce covariates through θ as θ =
exp(x′ β). The resulting model becomes

1

Sa (t|x) = [1 + exp(−a exp(x′ β)) − exp(−a exp(x′ β)S(t))] a .

(4.2.10)
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Figure 4.2: Comparison of survival functions from our model (a = 0.2) and the
hierarchical activation model (r − 1|N ∼ Bin(N − 1, 0.2)).
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The regression coefficients affect both the probability of cure and the survival
time for non-cured individuals.

4.3

Model Identifiability

Identifiability is important for one to get unique estimates of model parameters.
Li et al. [60] studied the identifiability of the mixture model and the bounded
cumulative hazard model in the context of bounded observation times. In Section
4.3.1, we present identifiability results of our proposed model. We further establish
identifiability properties of the latent hierarchical activation model of Cooner et al.
[19] in Section 4.3.2. Unlike Li et al. [60], our study allows the observation time to
be unbounded.

4.3.1

Identifiability of the New Model

In this subsection, we examine the identifiability of our proposed cure model.
Here we focus on the special case (4.2.9). Let F = {F (t; γ) : γ ∈ Γ} be the
class of proper failure time distributions on [0, ∞). Denote H = {Sa (t) : Sa (t) =
1

[1 + exp(−aθ) − exp(−aθS(t))] a ; S(·) = 1 − F (·), F (·) ∈ F , a ∈ R, θ ∈ (0, ∞).} as
the class of cure models of the form (4.2.9). Following the approach of Titterington,
Smith, and Markov [91], the identifiability of model (4.2.9) is defined as:
Definition 4.3.1. The class of cure models H is identifiable if, for any two Sa1 ∈
H , Sa2 ∈ H , Sa,1 (t) = Sa,2 (t) for all t ∈ [0, ∞) if and only if S1 (t) = S2 (t) for all
t ∈ [0, ∞), θ1 = θ2 and a1 = a2 .
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Figure 4.3: Comparison of survival functions from our model (a = 0.5) and the
hierarchical activation model (r − 1|N ∼ Bin(N − 1, 0.5)).
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Suppose there exist (a1 , θ1 , S1 (t)) and (a2 , θ2 , S2 (t)) such that
1

1

(1 + exp(−a1 θ1 ) − exp(−a1 θ1 S1 (t))) a1 = (1 + exp(−a2 θ2 ) − exp(−a2 θ2 S2 (t))) a2 .

Let t → ∞; it gives exp(−θ1 ) = exp(−θ2 ) and thus θ1 = θ2 , i.e., θ is identifiable.
However, a and S(t) are not identifiable in general. Given an arbitrary set of a1 , a2
and S1 (t), we can define S2 (t) from the equation
1

1

(1 + exp(−a1 θ) − exp(−a1 θS1 (t))) a1 = (1 + exp(−a2 θ) − exp(−a2 θS2 (t))) a2 .

Clearly, S2 (t) is a proper survival function. Consequently, we need to make additional assumptions for the new model to be identifiable.
Theorem 4.3.1. Model (4.2.9) is identifiable if F(t)=1-S(t) is specified as a parametric distribution indexed by a finite set of parameters, such as Weibull, gamma,
lognormal, and piecewise exponential distribution.
Proof. Suppose S(t) is indexed by γ and there exist a1 , a2 , γ1 and γ2 such that
1

1

(1 + exp(−a1 θ) − exp(−a1 θS1 (t; γ1 ))) a1 = (1 + exp(−a2 θ) − exp(−a2 θS2 (t; γ2 ))) a2 .
Then

S2 (t; γ2 ) = −

n
a2 o
1
log 1 + e−a2 θ − (1 + e−a1 θ − e−a1 θS1 (t;γ1 ) ) a1 .
θ2

This relationship must be independent of θ, a1 and a2 , and hold for all t ∈ [0, ∞). It
is obvious that S1 (t; γ1 ) and S2 (t; γ2 ) cannot have the same parametric form unless
a1 = a2 and hence γ1 = γ2 .
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The above result is similar to Theorem 5 in Li et al. [59]. The following theorem
establishes the identifiability of the regression model (4.2.10).
Theorem 4.3.2. Let Sa (t) be defined in (4.2.10) and let θ = exp(β0 +β1 x). Assume
S(t) can take values other than 0 and 1. Then, if β1 6= 0 and x has support that
contains an open set, a, β0 , β1 and S(t) are identifiable.
Proof. Consider
1

Sa (t) = [1 + exp(−a exp(β0 + β1 x)) − exp(−a exp(β0 + β1 x)S(t))] a .

(4.3.1)

If S(t) = 0 or 1, Sa (t) will be independent of a. Otherwise, as long as x takes four
different values and β1 6= 0, Sa (t) is uniquely represented in form (4.3.1) by a, β0 ,
β1 and S(t) for all t.
To generalize the above theorem to the case of more than one covariate is straightforward. Also, the conditions imposed in this theorem are not uncommon in many
clinical studies. It turns out that, if a dataset contains sufficiently many different
θ’s, the parameter a can be accurately estimated. We will later demonstrate this in
Section 4.4. The results in this subsection can be generalized to model (4.2.1). To
avoid redundancy, we skip the discussion of other choices of A(θ) here.

4.3.2

Identifiability of the Latent Activation Model

In the latent hierarchical activation model of Cooner et al. [19], one assumes that
there are N latent factors, each having a latent activation time Yj , j = 1, . . . , N,
with a distribution function F (t) and survival function S(t) = 1 − F (t). The event
occurs when r out of N latent factors are activated. It is further assumed that
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the random variable N, r, and Yj ’s are all independent. According to Cooner et
al. [19], if the activation threshold r is a deterministic function of the number of
latent factors N, the overall survival function under the latent hierarchical activation
scheme is given by

∞ r(j)−1
X
X j 
(F (t))k (S(t))j−k P (N = j)
S1 (t) = P (N = 0) +
k
j=1 k=0

= P (N = 0) +

∞
X

IB(S(t), j − r(j) + 1, r(j))P (N = j),

(4.3.2)

j=1

where IB(S(t), j − r(j) + 1, r(j)) denotes the incomplete Beta function or Beta cdf.
If r is treated as a random variable and assumed to be independent of the latent
promotion times of tumor cells, the survival function for T is written as
)
( r−1  
j
∞ X
X j
X
(F (t))k (S(t))j−k g(r|N = j)P (N = j)
S2 (t) = P (N = 0) +
k
j=1 r=1
k=0
= P (N = 0) +

j
∞ X
X

IB(S(t), j − r + 1, r)g(r|N = j)P (N = j), (4.3.3)

j=1 r=1

where g(r|N = j) denotes the probability mass function of the conditional distribution of r given N. Two special cases are the first-activation model and the
last-activation model whose survival functions are

SF A (t) =

∞
X

P (N = j)[F (t)]j

(4.3.4)

j=0

and
SLA (t) = 1 + P (N = 0) −

∞
X
j=0

P (N = j)[F (t)]j

(4.3.5)
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respectively.
Let F = {F (t; γ) : γ ∈ Γ} be the class of proper failure time distributions
on [0, ∞). Let P = {P (n; θ) : θ ∈ Θ} be the class of proper probability mass
functions on non-negative integers with finite mean. Let A = {r(N) : r(N) ∈
[1, N], r(N) ∈ N, N ∈ N} be a subset of the class of functions on natural numbers.
Let G = {g(r|N) : N ∈ N} denote the class of proper conditional probability
mass function on positive integers in [1, N]. Let H1 = {S1 (t) : S1 (t) = P (N =
P
0) + ∞
j=1 IB(S(t), j − r(j) + 1, r(j))P (N = j), P (·) ∈ P, S(·) = 1 − F (·), F (·) ∈

F , r(·) ∈ A } be the class of survival functions under fixed activation schemes.
P Pj
Let H2 = {S2 (t) : S2 (t) = P (N = 0) + ∞
r=1 IB(S(t), j − r + 1, r)g(r|N =
j=1
j)P (N = j), P (·) ∈ P, S(·) = 1 − F (·), F (·) ∈ F , g(·) ∈ G } be the class of

survival functions under random activation schemes. Note that H1 ⊆ H2 . Then
the identifiability of the latent activation cure models is defined as follows:
Definition 4.3.2. The class of latent activation cure models H1 is identifiable if
P
for any two members of H1 given by S1,1 (t) = P1 (N = 0) + ∞
j=1 IB(S1 (t), j −
P
r1 (j) + 1, r1 (j))P1 (N = j) and S1,2 (t) = P2 (N = 0) + ∞
j=1 IB(S2 (t), j − r2 (j) +
1, r2 (j))P2 (N = j), S1,1 (t) ≡ S1,2 (t) if and only if P1 (n) ≡ P2 (n) for n ∈ N,
S1 (t) ≡ S2 (t) for t ∈ [0, ∞), and r1 (n) ≡ r2 (n) for P (n) 6= 0.
Definition 4.3.3. The class of latent activation cure models H2 is identifiable if
P Pj
for any two members of H1 given by S2,1 (t) = P1 (N = 0) + ∞
j=1
r=1 IB(S(t), j −
P Pj
r + 1, r)g1(r|N = j)P1 (N = j) and S2,2 (t) = P2 (N = 0) + ∞
r=1 IB(S(t), j −
j=1

r + 1, r)g2 (r|N = j)P2 (N = j), S2,1 (t) ≡ S2,2 (t) if and only if P1 (n) ≡ P2 (n) for

n ∈ N, S1 (t) ≡ S2 (t) for t ∈ [0, ∞), and g1 (r|N = n) ≡ g2 (r|N = n) for 1 6 r 6 n
and P (n) 6= 0.
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Again, we allow T to be unbounded in our discussion. Therefore, by letting
T → ∞, it is straightforward to observe that the equality of the two overall survival
functions implies the equality of the two cure rates, i.e., both S1,1 (t) = S1,2 (t) and
S2,1 (t) = S2,2 (t) imply P1 (N = 0) = P2 (N = 0). Under our definition, a necessary
condition for the class of latent activation cure models to be identifiable is that at
least two of the three latent components, P (·), F (·) and g(·), must be specified.
Otherwise, if only one of the three components is specified, the model is generally
not identifiable. Below are two examples.
Example 4.3.1. Suppose P is specified as P oisson(θ). Given an F1 with a firstactivation scheme, we can define an F2 with a last-activation scheme by equating
exp(−θF1 (t)) = 1+exp(−θ)−exp(−θS2 (t)) and get S2 (t) = −(1/θ) log(1+exp(−θ)−
exp(−θF1 (t))). Clearly, S2 (t) is a valid proper survival function. Thus we have both
(P , F1 , first activation) and (P , F2 , last activation) yielding the same model.
Example 4.3.2. Suppose the activation scheme is fixed to be first activation but
P and F are left unspecified. Let P1 be specified as P oisson(θ) and thus the overall
survival function is S1,1 = exp(−θF1 (t)). Let P2 be a geometric distribution with
mass function P2 (N = j) = θ∗ /(θ∗ + 1)j+1 , j > 0. Then the overall survival function
is S1,2 (t) = (1+θ∗F2 (t))−1 . This is the model considered by Gu et al. [41]. These two
models are equivalent if θ∗ = eθ −1 and F2 (t) = (eθF1 (t) −1)/θ∗ = (eθF1 (t) −1)/(eθ −1).
Actually, F1 and F2 are often very close to each other.
In the following, we establish the identifiability of the models under a variety of
conditions.
Case 1 : P (·) and g(·) are completely specified.
Theorem 4.3.3. In Case 1, the class H2 (and thus H1 ) is identifiable.
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Proof. Let S2 (t) be specified as (4.3.3). Since P (·) and g(·) are completely specified,
P (N = j) and g(r|N = j) are fixed quantities for each j and r. Let us fix a time
point t. Then we can regard S2 (t) as a function of S(t). Since the Beta cdf is strictly
increasing, S2 (t) is a strictly increasing and one-to-one function of S(t). Therefore,
S2,1 (t) = S2,2 (t) if and only if S1 (t) = S2 (t). And this is true for each t.
Corollary 4.3.4. The class H2 (and thus H1 ) is identifiable if g is completely specified and P is a power series distribution with probability mass function P (n; θ) =
cn θn /A(θ), where θ > 0 is the parameter, cn > 0, cn > 0 for some n > 0, are fixed
P
n
constants, and A(θ) = ∞
n=0 cn θ .
Proof. We will prove that P is unique and the corollary will follow from Theo-

rem 4.3.3. Suppose S2,1 (t) = S2,2 (t) and let t → ∞, we get P1 (0) = P (0; θ1) =
c0 /A(θ1 ) = c0 /A(θ2 ) = P (0; θ2) = P2 (0). Since A(θ) is a strictly increasing and
one-to-one function of θ, this implies θ1 = θ2 and thus the uniqueness of P .

Case 2 : F (·) and g(·) are completely specified and the range of F contains an open
set. To proceed, we first introduce the following lemma.
Lemma 4.3.5. For each i = 1, · · · , N, let Fi , be the class of distribution functions
of Beta(ki , i + 1 − ki ), where 1 6 ki 6 i, ki ∈ N. The class of finite mixtures of Beta
P
distributions of the form B = {B(x) : B(x) = w0 + N
i=1 wi Fi (x), Fi ∈ Fi , wi >
P
0, N
i=0 wi = 1, N ∈ N, x ∈ [0, 1]} is identifiable. In other words, if B1 , B2 ∈ B and
P 1
PN2
B1 = w1,0 + N
i=1 w1,i F1,i = w2,0 +
j=1 w2,j F2,j = B2 , then N1 = N2 , w1,0 = w2,0 ,
and for each 1 6 i 6 N1 , there is some j, 1 6 j 6 N1 , such that w1,i = w2,j and
F1,i = F2,j .
(n)

Proof. For each Fi ∈ Fi , denote its nth derivative as Fi . Then, for each i,
(i)

Fi

(n)

> 0 and Fi

= 0 for n > i. Thus, the Wronskian of 1, F1 , · · · , FN is non-zero
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on (0, 1). Therefore, the set of functions 1, F1 , · · · , FN are linearly independent,
which implies the uniqueness of the representation of each B ∈ B (Yakowitz and
Spragins [101]).
Theorem 4.3.6. In Case 2, the class H1 is identifiable if P has finite support.
P 1
Proof. Let S1,1 (t) = P1 (0) + M
j=1 IB(S(t), j − r(j) + 1, r(j))P (N = j) and S1,2 (t) =
PM2
P2 (0) + j=1 IB(S(t), j − r(j) + 1, r(j))P (N = j), M1 , M2 < ∞. By Lemma 4.3.5,
S1,1 = S1,2 if and only if M1 = M2 and P1 (j) = P2 (j) for each j.

If the activation scheme is random, then P is generally not identifiable.
Example 4.3.3. Let g(r|N) = 1/N for each 1 6 r 6 N. Let P1 (0) = 0.2, P1 (1) =
0.4, P1 (2) = 0.4 and P2 (0) = 0.2, P2 (1) = 0.3, P2 (2) = 0.5. Then it can be verified
that (P1 , S, g) and (P2 , S, g) yield the same survival function S ∗ (t) = 0.2 + 0.8S(t).
Theorem 4.3.7. In Case 2, if P has infinite support, then the class H1 is identifiable if r(j) = 1 for each j (first activation) or r(j) = j for each j (last activation).
Proof. Under first activation, S1 (t) =

P∞

j=0

P (N = j)[S(t)]j defines an absolutely

convergent power series in S(t) on [0, 1]. Therefore, if the range of S(t) contains an
open set, S1 (t) has unique representation. This implies the uniqueness of P . The
proof for last activation is similar.

Case 3 : F (·) and P (·) are completely specified and the range of F contains an open
set.
Theorem 4.3.8. In Case 3, the class H1 , i.e., any fixed activation scheme, is
identifiable if P has finite support.
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P
Proof. Let S1,1 (t) = P (N = 0) + M
j=1 IB(S(t), j − r1 (j) + 1, r1 (j))P (N = j) and
PM
S2,2 (t) = P (N = 0) + j=1 IB(S(t), j − r2 (j) + 1, r2 (j))P (N = j), M < ∞. Then
by Lemma 4.3.5, S1,1 (t) = S1,2 (t) if and only if r1 (j) = r2 (j) for each j.

However, even if both F and P are fully specified, the random activation scheme is
generally not identifiable.
Example 4.3.4. Let P (0) = P (1) = P (2) = P (3) = 1/4. Let g1 (r|N) = 1/N.
Let g2 (1|2) = 3/4, g2 (2|2) = 1/4; g2 (1|3) = 1/6, g2 (2|3) = 1/3, g2 (3|3) = 1/2.
It can be verified that (P , S, g1 ) and (P , S, g2 ) yield the same survival function
S ∗ (t) = 0.25 + 0.75S(t).
Theorem 4.3.9. In Case 3, if P has infinite support, the first-activation scheme
and the last-activation scheme are identifiable.
This follows from the fact (Kim et al. [51]) that any activation scheme other
than the first activation is stochastically larger than the first-activation scheme and
that any activation scheme other than the last-activation is stochastically smaller
than the last activation scheme.
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4.4

4.4.1

Numerical Studies

The Likelihood, Prior and Posterior

In this section, we illustrate the properties of model (4.2.10) via a simulation
study and two datasets. The survival, density, and hazard functions are given by
1

Sa (t) = [1 + exp(−a exp(x′ β)) − exp(−a exp(x′ β)S(t))] a ;
ha (t) =

exp(−a exp(x′ β)S(t))θf (t)
;
1 + exp(−a exp(x′ β)) − exp(−a exp(x′ β)S(t))

fa (t) = Sa (t) × ha (t).

We specify F (t) as a Weibull distribution, W eib(α, η), with survival function
S(t) = exp(−eη tα ) for all subsequent analysis. For the ith individual, let Di =
(yi , δi , xi ) denote the observed data, where yi = min(Ti , Ci ) is the minimum of the
failure time and the censoring time and δi = I[Ti 6 Ci ] is the censoring indicator.
Let Ω = (β, α, η, a) denote the model parameters and D = {Di }ni=1 . The likelihood
function is given by

L(Ω|D) =

n
Y
i=1

L(Ω|Di ) =

n
Y

Sa (yi |Ω, xi )[ha (yi |Ω, xi )]δi .

i=1

We assume that all the parameters are a priori independent and specify the prior
distribution on Ω as π(Ω) = π1 (β)π2 (α)π3 (η)π4 (a). We always use a N(0, 100) prior
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for η and each component of β, a Gamma(0.1, 0.1) prior for α and a uniform prior
for a. The posterior distribution of Ω is

p(Ω|D) ∝ L(Ω|D) × π(Ω).

The marginalization of p(Ω|D) can be achieved by MCMC algorithms. For each
data analysis, we run two initially dispersed parallel MCMC chains to monitor the
convergence of the posterior distribution.
We use the log pseudo-marginal likelihood (LPML) (Geisser and Eddy [36]) as
the criterion for model comparison. For time-to-event data, we compute the LPML
as

LP ML =

n
X
i=1

=

n
X
i=1


log fa (yi |D−i , xi )δi Sa (yi |D−i , xi )1−δi
log

Z

δi

fa (yi |Ω, xi ) Sa (yi |Ω, xi )

1−δi


p(Ω|D−i )dΩ , (4.4.1)

where D−i denotes the observed data with the ith subject deleted.

4.4.2

Simulation Study

We assessed the performance of our proposed model by a simulation study. We
set F (t) to be a Weibull distribution with shape parameter α = 1.5 and scale
parameter λ = 6. In computation, we reparameterized the density function by
letting η = −α log λ such that S(t) = exp(−eη tα ). We let θ = exp(β0 + β1 x) and
set β0 = 0.5 and β1 = 1. The covariates were generated from the standard normal
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distribution. We generated 100 datasets each for a =0, 0.2, 0.5, 0.7 and 1. Each
dataset has sample size 100 with moderate censoring. For each replicated dataset, we
computed the posterior median, the posterior mean, and the 95% credible interval
for each parameter. To assess model performance, we then computed the bias of each
estimator by taking the absolute difference between the data-generating values and
the averages of the posterior median and the posterior mean over the 100 replicated
datasets. A 95% confidence interval for each parameter was obtained by taking the
2.5% and 97.5% percentiles of the posterior median and the posterior mean over the
100 replicated datasets. We also computed the coverage of the 95% credible interval
by counting the number of times the interval contains the data-generating value.
Table 4.2 summarizes the estimation results using the correct model. A U(0, 1)
prior is used for the parameter a. The results in Table 4.2 indicate that the proposed
model performs well in estimation. The bias is small and the coverage is accurate.
It is also observed that the parameter a can be well estimated even if its true value
is on the boundary of the uniform prior distribution. And its estimates can be
improved when a uniform prior with a broader range is used.
We also assessed the performance of the first-activation model and the lastactivation model when they were different from the data-generating models. Tables
4.3 and 4.4 summarize these results. From Table 4.3, one can see that the firstactivation model performs poorly in estimating the regression coefficient β1 and the
Weibull parameter λ, as is shown by large bias of the point estimators and low
coverage of the credible intervals. Furthermore, the first-activation model can fail
to detect a significant covariate when the data-generating model is close to the last
activation. Similar results are observed in Table 4.4, except that the last activation
still performs reasonably well when it is close to, though different from, the datagenerating model.
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Table 4.2: Performance of Bayesian estimates under the proposed model for 100
replicated datasets.
DGM1
a=0
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a = 0.2
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a = 0.5
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a = 0.7
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a=1
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a=1
β0 = 0.5
β1 = 1
α = 1.5
λ=6
1
2
3
4

Posterior Median
Bias
95% CI2
0.039 (0.009, 0.110)
0.026 (0.153, 0.848)
0.065 (0.780, 1.320)
0.067 (1.187, 1.734)
0.094 (4.115, 8.447)
0.014 (0.071, 0.439)
0.005 (0.139, 0.914)
0.007 (0.670, 1.377)
0.003 (1.257, 1.825)
0.047 (3.940, 9.037)
0.016 (0.252, 0.787)
0.028 (0.142, 0.987)
0.016 (0.656, 1.388)
0.016 (1.219, 1.909)
0.117 (4.556, 8.430)
0.020 (0.353, 0.888)
0.015 (0.222, 0.827)
0.076 (0.588, 1.481)
0.010 (1.139, 1.920)
0.123 (4.656, 7.909)
0.262 (0.472, 0.884)
0.104 (0.255, 0.991)
0.070 (0.689, 1.488)
0.109 (1.304, 2.015)
1.099 (5.587, 9.337)
0.045 (0.485, 1.277)
0.043 (0.213, 0.950)
0.040 (0.672, 1.485)
0.044 (1.208, 1.945)
0.272 (4.519, 8.867)

DGM = Data-generating model
CI = Confidence interval
The prior used for a is U (0, 1).
The prior used for a is U (0, 1.5).

Posterior Mean
Bias
95% CI2
0.047 (0.013, 0.123)
0.045 (0.156, 0.946)
0.067 (0.781, 1.324)
0.064 (1.189, 1.737)
0.642 (4.231, 13.092)
0.033 (0.078, 0.467)
0.010 (0.141, 1.016)
0.005 (0.669, 1.375)
0.007 (1.259, 1.833)
0.471 (4.017, 10.919)
0.029 (0.278, 0.764)
0.037 (0.158, 1.017)
0.015 (0.657, 1.389)
0.021 (1.221, 1.913)
0.376 (4.642, 9.618)
0.029 (0.389, 0.859)
0.021 (0.220, 0.832)
0.075 (0.571, 1.482)
0.003 (1.144, 1.928)
0.336 (4.782, 8.321)
0.279 (0.498, 0.857)
0.109 (0.257, 0.998)
0.066 (0.666, 1.489)
0.117 (1.312, 2.028)
1.315 (5.766, 9.798)
0.050 (0.531, 1.232)
0.049 (0.219, 0.947)
0.038 (0.662, 1.484)
0.052 (1.222, 1.948)
0.460 (4.739, 9.141)

Coverage
-3
97
97
93
92
92
95
95
99
93
96
94
94
98
98
97
99
92
89
99
-3
93
95
93
94
974
96
96
98
100
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Table 4.3: Performance of Bayesian estimates under the first-activation model (i.e.
fix a = 0) for 100 replicated datasets.
DGM1
a = 0.2
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a = 0.5
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a = 0.7
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a=1
β0 = 0.5
β1 = 1
α = 1.5
λ=6
1
2

Posterior Median
Bias
95% CI2
0.022 (0.103, 1.033)
0.391 (0.367, 0.966)
0.116 (1.300, 1.991)
1.893 (5.450, 13.36)
0.088 (0.011, 1.499)
0.641 (0.151, 0.646)
0.230 (1.264, 2.210)
6.468 (7.363, 30.23)
0.123 (0.013, 1.694)
0.732 (0.081, 0.522)
0.259 (1.396, 2.211)
8.446 (8.401, 34.58)
0.149 (0.061, 2.199)
0.802 (-0.070, 0.415)
0.377 (1.410, 2.645)
11.38 (9.180, 42.12)

DGM = Data-generating model
CI = Confidence interval

Posterior Mean
Bias
95% CI2
0.051 (0.116, 1.456)
0.392 (0.368, 0.966)
0.117 (1.304, 1.993)
12.66 (5.596, 84.13)
0.218 (0.027, 2.119)
0.641 (0.150, 0.647)
0.234 (1.275, 2.213)
51.004 (7.617, 253.7)
0.283 (0.069, 2.117)
0.732 (0.079, 0.522)
0.264 (1.410, 2.215)
28.775 (8.941, 127.8)
0.288 (0.086, 2.307)
0.802 (-0.073, 0.414)
0.383 (1.427, 2.646)
24.89 (9.697, 127.3)

Coverage
97
17
93
93
93
1
77
27
96
0
86
9
98
0
72
0
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Table 4.4: Performance of Bayesian estimates under the last-activation model (i.e.
fix a = 1) for 100 replicated datasets.
DGM1
a=0
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a = 0.2
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a = 0.5
β0 = 0.5
β1 = 1
α = 1.5
λ=6
a = 0.7
β0 = 0.5
β1 = 1
α = 1.5
λ=6
1
2

Posterior Median
Bias
95% CI2
0.164 (-0.049, 4.266)
0.733 (-0.651, 0.637)
0.599 (0.184, 1.217)
4.068 (0.002, 2.966)
0.128 (0.033, 3.040)
0.431 (-0.390, 0.872)
0.345 (0.375, 1.436)
3.142 (0.193, 3.595)
0.144 (0.063, 0.748)
0.164 (0.544, 1.272)
0.142 (1.090, 1.668)
1.723 (3.442, 4.985)
0.076 (0.091, 0.782)
0.068 (0.585, 1.312)
0.098 (1.161, 1.717)
1.066 (4.028, 5.875)

Posterior Mean
Bias
95% CI2
0.197 (-0.054, 4.108)
0.735 (-0.650, 0.637)
0.595 (0.215, 1.219)
4.050 (0.049, 2.969)
0.121 (0.030, 2.949)
0.430 (-0.268, 0.871)
0.340 (0.476, 1.442)
3.230 (0.030, 2.949)
0.144 (0.060, 0.747)
0.165 (0.541, 1.276)
0.137 (1.095, 1.672)
1.720 (3.438, 4.997)
0.076 (0.093, 0.782)
0.069 (0.575, 1.311)
0.092 (1.169, 1.717)
1.063 (4.028, 5.876)

Coverage
42
1
1
0
54
22
42
0
83
82
81
6
96
91
92
56

DGM = Data-generating model
CI = Confidence interval

Overall, these results indicate that both the first-activation model and the lastactivation model can lead to biased inference on the cure rate when they are different
from the underlying data-generating process.

60

4.4.3

Colon Cancer Data

In a colon cancer study reported by Moertel et al. [68], 929 patients with stage C
disease were randomized to three adjuvant therapies, with 315 patients on the control
arm, 310 receiving levamisole (Lev) and 304 receiving a combination of levamisole
(Lev) and flourouracil (5-FU). All enrolled patients had undergone a potentially
curative surgical resection of disease tumors without gross or microscopic evidence
of residual disease. All patients were evaluated at the same time intervals for disease
recurrence. While the study was terminated after an interim analysis in which
Lev+5-FU was found to be highly effective in prolonging survival and preventing
recurrence, follow-up was continued in patients for a maximum of about 9 years.
Here, we focus on the analysis of time to recurrence.
The Kaplan-Meier curve (Figure 4.4) shows an obvious plateau for each of three
treatment arms and suggests a cure model is appropriate to model the data. We
fitted data using our proposed model. The covariates included in our analysis are
treatment, age, gender (0=female; 1=male), and number of positive lymph nodes
(0 = 6 4 nodes; 1 = more than 4 nodes). To take into consideration a wide range
of possible activation schemes, we used a Uniform(-20,20) prior on the parameter a.
Table 4.5 gives the posterior mean, posterior median, and 95% credible intervals for
each regression coefficient. We first observed that 95% credible interval for a does
not contain 0 or 1. This suggests that the underlying data-generating process is
probably different from the first-activation model or the last-activation model. The
results in Table 4.5 shows that levamisole plus fluorouracil significantly improves
the cure rate of the disease when compared with the control arm, after adjusting
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for other covariates. It is also observed that gender is not a significant factor that
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Lev + 5−FU

0.0
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1.0

affects the improvement in the cure rate.
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2

4

6

8

Time (in years)

Figure 4.4: Kaplan-Meier curves of colon cancer recurrence in all patients.

Table 4.5: Bayesian posterior estimates of the colon cancer data from the proposed
model.
Parameter
Median
Intercept
-0.32
Treatment (Control=0)
Levamisole -0.022
Lev+5-FU
-0.38
Age
-0.029
Nodes
0.67
Gender
-0.098
a
-1.23
LPML
-1221.7

Mean
-0.32

95% Credible Interval
(-0.48, -0.16)

-0.022
-0.38
-0.028
0.67
-0.1
-1.31

(-0.17, 1.24)
(-0.61, -0.20)
(-0.098, 0.004)
(0.47, 0.88)
(-0.24, 0.034)
(-2.38, -0.57)
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For comparison, Table 4.6 displays the estimation results from the first-activation
model and the last-activation model. Although there is no change in the significance of the covariates, the LPML shows our proposed model is better than the
first-activation model or the last-activation model. As we discussed earlier, the
first-activation model assumes that the event is observed if any one tumor cell is
activated, and we have shown that when a < 0 the event is observed faster than the
first activation. Then one may wonder whether a negative value of a could have a
reasonable interpretation here. Peng and Xu [74] interpreted the amount of tumor
cells as tumor volumes instead of number of cells. We can interpret our results
similarly here as that the event is observed if a fraction of one unit volume of tumor
is activated.

Table 4.6: Bayesian posterior estimates of the colon cancer data from the firstactivation model and the last-activation model.
First-activation Model
Last-activation Model
1
Parameter
Median Mean
95% CI
Median Mean
95% CI1
Intercept
-0.34
-0.34 (-0.53, -0.15)
-0.36
-0.36 (-0.56, -0.18)
Treatment (Control=0)
Levamisole -0.013 -0.011 (-0.22, 0.20)
-0.024 -0.027 (-0.24, 0.20)
Lev+5-FU
-0.52
-0.52 (-0.76, -0.29)
-0.46
-0.46 (-0.70, -0.23)
Age
-0.044 -0.043 (-0.14, 0.048) -0.032 -0.031 (-0.12, 0.064)
Nodes
0.88
0.88
(0.68, 1.08)
0.60
0.60
(0.40, 0.79)
Gender
-0.092 -0.094 (-0.28, 0.087) -0.004 -0.005 (-0.19, 0.17)
LPML
-1238.3
-1264.3
1

CI = Credible interval
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4.5

Discussion

In this chapter, we proposed a class of stochastically ordered cure models that
include several existing models as special cases. We showed that our model is identifiable under pretty general conditions. We also demonstrated the performance of
our model and the advantage of our model over the first-activation and the lastactivation models. Our work can be readily extended to frailty models to incorporate patient heterogeneity. It is also possible to develop a multivariate version
of our model, to adopt our framework to the joint modeling of survival time and
longitudinal data, and to accommodate the situations in which a patient is simultaneously exposed to two or more competing risks and one or more risks have a
cure fraction. The flexibility of our proposed model makes it a good candidate for
modeling survival data with a cure fraction.

CHAPTER 5
A NEW COMPETING RISKS MODEL

5.1

Introduction

When patients are simultaneously exposed to more than one risk, it is difficult
to assess the cure possibility of a risk from its Kaplan-Meire curve. This is because
the cumulative incidence rate from each risk is necessarily strictly less than one.
Thus, a single cure model may not be sufficient for data arising from such context.
Furthermore, it is more practical to assume that patients subject to competing risks
will eventually fail from one of them. Therefore, a comprehensive competing risks
model is necessary to analyze the behavior, including the cure possibility, of each
risk in presence of other ones.
Let T be the survival time for a disease with a cure fraction. Then the distribution function for T and the cumulative incidence function share a common property
that they are both improper. This makes cure model a potential candidate for the
cumulative incidence function. In formulating their semiparametric model, Fine
and Grey [32] constructed an unusual hazard function (2.4.14) that permanently includes subjects who experienced the event from other causes in the current risk set.
They defended such a construction by arguing that the same had been used in cure
models. The Gompertz distribution (2.4.17) considered by Jeong and Fine [48] is
itself a viable choice for modeling survival time with a cure fraction (Tsodikov et al.
[94]). Indeed, subjects who experienced the event from other causes will definitely
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not experience the event again from the risk of interest as if they were cured. In
this chapter, we introduce a new model for the cumulative incidence function using
the bounded cumulative hazard model. We show that the model has several desirable mathematical properties along with a meaningful biological interpretation. In
particular, the overall survival function derived from our proposed model is proper.

5.2

The Model

Let Fj (t), j = 1, . . . , K, be the cumulative incidence function for the jth cause.
Then Sj∗ (t) = 1 − Fj (t) represents the probability of either not failing from the jth
cause before time t or having failed from other causes as of time t. Note that Sj∗ (t)
is an improper survival function. Its limiting value

lim Sj∗ (t) = 1 − lim Fj (t) = 1 − P (C = j)

t→∞

t→∞

(5.2.1)

is strictly positive in presence of two or more competing risks. Thus, each Sj∗ (t) can
be modeled by a bounded cumulative hazard model. Let pj = Fj (∞) = P (C = j),
j = 1, . . . , K, be the probability of observing a failure from the jthe cause in presence
P
of K competing risks, where pj > 0 for each j and K
j=1 pj = 1. Using the bounded
cumulative hazard model, Sj∗ (t) is written as

Sj∗ (t) = e−θj F0j (t) ,

(5.2.2)

where F0j (t) is the proper distribution function of some nonnegative random variable
and θj satisfies
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e−θj = 1 − pj ,

(5.2.3)

θj = − log(1 − pj ).

(5.2.4)

or equivalently,

Then the cumulative incidence function Fj (t) has the form

Fj (t) = 1 − e−θj F0j (t) = 1 − (1 − pj )F0j (t) .

(5.2.5)

Our model has several desirable properties. First, we have lim Fj (t) = pj =
t→∞

P (C = j). Therefore, in this formulation, the limit of the sum of cumulative
incidence functions is one by construction. In a Bayesian setting, to ensure this
condition is satisfied in computation, we can assign a Dirichlet prior distribution on
(p1 , . . . , pK ). If there are only two risks, a uniform or Beta prior on p1 will suffice.
Second, using (5.2.5), the overall survival function is

S(t) = 1 −

K
X

Fj (t) =

j=1

Note that lim S(t) =
t→∞

K
X

e−θj F0j (t) − (K − 1) =

j=1

j=1

PK

j=1 (1

K
X
(1 − pj )F0j (t) − (K − 1). (5.2.6)

− pj ) − (K − 1) = 0. Therefore, the overall survival

function (5.2.6) is proper, as a survival function in presence of competing risks
should be.
Third, the hazard function (2.4.14) corresponding to the cumulative incidence
function, as defined by Fine and Grey [32], is
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hj (t) = θj f0j (t),

(5.2.7)

which has a proportional hazard structure. Here f0j (t) is the density function of
F0j (t), which we assume exists. In addition, depending on the choice of f0j (t), this
hazard function can be either monotone or unimodal, or have other shapes. This is
more flexible than the Gompertz distribution used by Jeong and Fine [48], whose
hazard function can only be monotone.
Finally, we can derive our model from a latent activation process similar to
that of Chen et al. [14]. Let Nj∗ be a random variable representing the number of
latent factors underlying the jth cause in presence of other competing risks. Let
Tj1 , . . . , TjNj∗ be the activation times for each factor. Suppose that
(1) Nj∗ is distributed as Poisson with mean θj such that e−θj = 1 − pj ;
(2) Conditional on Nj∗ , Tj1 , . . . , TjNj∗ are independently and identically distributed
as F0j (t);
(3) Nj∗ and Tj1 , . . . , TjNj∗ are independent;
(4) The event is observed if any one of the factors is activated.
Then, using the same derivation process of Chen et al. [14], Sj∗ (t) can be shown to
be exactly the same as (5.2.2).

5.3

Estimating the Cure Rate

As we discussed earlier, while it makes more sense that, in presence of competing
risks, a subject will eventually experience the event from one of them, it is still
possible that a subject is cured from some of them. Our model allows up to K − 1
individual risks to have a non-zero cure rate. Let
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 Z
cj = exp −

∞

0


λj (t)dt

(5.3.1)

be the cause-specific cure rate for cause j as defined in (3.6.3). Since the causespecific function λj (t) and the cumulative incidence function have the following
relationship:

λj (t) =

dFj (t)
dFj (t)
,
=
PK
S(t)
1 − j=1 Fj (t)

(5.3.2)

the cause-specific cure rate can be expressed in terms of the cumulative incidence
functions as

cj = exp −

Z

∞
0

dFj (t)
PK
1 − j=1 Fj (t)

!

.

(5.3.3)

Using the bounded cumulative hazard formulation (5.2.5) for Fj (t), the above expression for cj can be further written as

cj = exp −

Z

0

∞

θj f0j (t) exp(−θj F0j (t))dt
PK

j=1 exp(−θj F0j (t))

− (K − 1)

!

.

(5.3.4)

Note that the integral in (5.3.4) can be written as

Z

0

∞

θj f0j (t) exp(−θj F0j (t))dt
PK

j=1 exp(−θj F0j (t)) − (K − 1)

= ET

θj exp(−θj F0j (t))
PK

j=1 exp(−θj F0j (t))

− (K − 1)

!

with respect to a random variable T that has density function f0j (t). Therefore, the
calculation of cj can be easily achieved via Monte Carlo simulations.
One distinct feature of our model is that we do not need any prior knowledge
of whether a risk can be cured or not. In the competing risks models of Basu and
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Tiwari [6] and Sarkar [85], one needs to explicitly assign a cure model to one of the
risks. When there is no competing risk, one can assess whether a cure fraction exists
by observing whether the survival curve levels off at a value strictly greater than
zero, or equivalently, whether the distribution function levels off at a value strictly
less than one. In presence of competing risks, all cumulative incidence functions
level off at some value less than one, regardless of whether the cure rate is zero or
not. Thus, it is difficult, if not impossible, to judge whether there is cure simply
by examining the graphical display. The use of the cause-specific hazard approach
then becomes limited.

5.4

Regression Models on the Cumulative Incidence
Function

Gray [40] and Fine and Gray [32] defined the hazard function (2.4.14) corresponding to the cumulative incidence function as

1
P (t < T ≤ t + ∆t, C = j|T ≥ t ∪ (T < t ∩ C 6= j))
∆t→0 ∆t
d log[1 − Fj (t)]
= −
.
dt

hj (t) =

lim

It can be thought of as the hazard function for the improper random variable Tj∗
such that Tj∗ = I(C = j)×T +I(C 6= j)×∞. It can be seen that Tj∗ has distribution
function Fj (t). In our formulation, we have

hj (t) = θj f0j (t) = − log(1 − pj )f0j (t)

(5.4.1)
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for each j. Then, if covariates are introduced through pj , j = 1, . . . , K, the resulting
model will have a proportional hazard structure.
We first consider the case when there are only two competing risks. The overall
survival function is

S(t) = e−θ1 F01 (t) + e−θ2 F02 (t) − 1 = (1 − p1 )F01 (t) + (1 − p2 )F02 (t) − 1,

(5.4.2)

where pj = 1 − e−θj , j = 1, 2. The two cumulative incidence functions are F1 (t) =
1 − (1 − p1 )F01 (t) and F2 (t) = 1 − (1 − p2 )F02 (t) respectively. Since p1 + p2 = 1, we
can adopt a binary regression model for p1 . The most popular model is the logistic
regression model, in which we have

p1 =

exp(x′ β)
,
1 + exp(x′ β)

(5.4.3)

where x is a m × 1 vector of covariates and β is a m × 1 vector of regression
coefficients. The advantage of the logistic model is that the regression coefficients
can be interpreted in terms of the odds of observing one event against the other.
Other models for binary response can also be considered. If a complementary log-log
model is used, we obtain

p1 = 1 − exp[− exp(x′ β)].

(5.4.4)

This is also the regression model used by Chen et al. [14] for their bounded cumulative hazard model. In this set-up, we have
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h1 (t; x) = exp(x′ β)f01 (t)

(5.4.5)

h2 (t; x) = − log[1 − exp(− exp(x′ β))]f02 (t).

(5.4.6)

and

We note that h1 (t; x) has a standard form of the proportional hazard model. On the
other hand, h2 (t; x) also satisfies the proportional hazard structure but it is a more
complex function of the regression parameters. In this model, a positive regression
coefficient leads to a higher probability of eventually observing the first event (and a
lower probability of eventually observing the second event), when the corresponding
covariate is positive.
In general cases, covariates can be introduced through (p1 , . . . , pK ) in the form
of a multinomial logistic regression model. The baseline-category logit model takes
the form

exp(x′ βj )
, j = 1, . . . , K − 1,
PK−1
1 + j=1 exp(x′ βj )
1
,
=
PK−1
1 + j=1 exp(x′ βj )

pj =
pK

(5.4.7)

where x is a m × 1 vector of covariates and each βj is a m × 1 vector of regression coefficients. If the competing risks involved have an ordinal scale (e.g., local, regional,
distant relapse), then we can also apply a cumulative logit model:

log

Pj

i=1 pi

PK

i=j+1 pi

!

= αj + x′ βj , j = 1, . . . , K − 1.

(5.4.8)
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If we require that all the βj ’s are the same, then (5.4.8) becomes the usual proportional odds model. The baseline-category logit model and the cumulative logit
model are very popular tools in a variety of disciplines. The regression coefficients
can be interpreted readily and meaningfully. When K = 2, both of them reduce to
the logistic regression model.
It needs to be noted that hj (t) defined above is not the cause-specific hazard
function for the jth cause. Gray [40] used these functions to test the equality
of the cumulative incidence functions. However, the inference on these functions
is not of primary scientific interest. The purpose of using these functions is to
facilitate the model building such that existing methods can be applied to analyze
the cumulative incidence functions. Using the regression models above, one can
predict the cumulative incidence of a risk at a given time conditional on the covariate
information.

5.5

5.5.1

The Bayesian Analysis

The Likelihood, Prior and Posterior

Let (ti , δi ), i = 1, . . . , n, represent the observed data for the ith individual,
where ti is the observed event or censoring time and δi = (δi1 , . . . , δiK )′ is the
censoring indicator for each risk. And we denote D = (t, δ) as the full observed
data. Let Ω0 = (p, γ) denote the model parameters, where p = (p1 , . . . , pK ) are
the probabilities of observing each event in presence of K competing risks (i.e., the
limiting values of each cumulative incidence function) and γ = (γ1 , . . . , γK ) are the
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parameter vectors that index F01 , . . . , F0K . Then the likelihood function is written
as

L0 (D|Ω0 ) =

n Y
K
Y

− log(1 − pj )f0j (ti |γj )(1 − pj )F0j (ti |γj )

i=1 j=1

×

K
X

(1 − pj )F0j (t) − (K − 1)

j=1

!1−PK
j=1 δij

δij

.

If K = 2, the above likelihood is reduced to

L0 (D|Ω0 ) =

n
Y

− log(p2 )f01 (ti |γ1 )p2 F01 (ti |γ1 )

i=1

δi1

δi2
× − log(p1 )f02 (ti |γ2 )p1 F02 (ti |γ2 )
1−δi1 −δi2
× p2 F01 (ti |γ1) + p1 F02 (ti |γ2) − 1
.
We assume that the prior distributions on p and γ1 , . . . , γK are a priori indepenQ
dent such that π(Ω0 ) = π(p) K
j=1 π(γj ). With such specification, the posterior
distribution of model parameters is given by

P0 (Ω0 |D) ∝ L0 (D|Ω0 ) × π(Ω0 ).

(5.5.1)

As mentioned earlier, a Dirichlet prior on p is an ideal choice. Then this posterior
distribution will be proper as long as each π(γj ) is proper.
If a regression model is built, the model parameters are denoted as Ω = (β, γ),
where β is m × 1 vector of regression coefficients and γ is the same as before. For
ease of illustration, we will only write out the likelihood function for the case of
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two competing risks here. If we use the complementary log-log model (5.4.4), the
likelihood function will be

L1 (D|Ω) =

n
Y

exp(x′i β)f01 (ti |γ1 )[exp(− exp(x′i β))]F01 (ti |γ1)

i=1

×(− log(1 − exp(− exp(x′i β)))f02 (ti |γ2 )

δi1

×[1 − exp(− exp(x′i β))]F02 (ti |γ2) )δi2
×([exp(− exp(x′i β))]F01 (ti |γ1 )
+[1 − exp(− exp(x′i β))]F02 (ti |γ2 ) − 1)1−δi1 −δi2 .
(5.5.2)

If a logistic model (5.4.3) is built, the likelihood function will be



F01 (ti |γ1) !δi1
1
1
L2 (D|Ω) =
− log
f01 (ti |γ1 )
′
1
+
exp(x
β)
1 + exp(x′i β)
i
i=1



F02 (ti |γ2 ) !δi2
exp(x′i β)
exp(x′i β)
×
− log
f02 (ti |γ2 )
1 + exp(x′i β)
1 + exp(x′i β)
!1−δi1 −δi2

F01 (ti |γ1) 
F02 (ti |γ2 )
′
1
exp(xi β)
×
+
−1
.
′
1 + exp(xi β)
1 + exp(x′i β)
n
Y



(5.5.3)

In all these models, each F0j (t|γj ) can be formulated either parametrically (Chen
et al. [14]) or semi-parametrically (Ibrahim, Chen and Sinha [47]). In this chapter,
we assume each F0j (t|γj ) is a Weibull distribution with density function

f0j (t|αj , ηj ) = αj eηj tαj −1 exp(−eηj tα ).

(5.5.4)
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In this formulation, γj = (αj , ηj ) and Ω = (β, α1 , α2 , η1 , η2 ). We assume that the
prior distributions on β, γ1 , and γ2 are a priori independent such that π(Ω) =
π(β)π(γ1 )π(γ2 ). We further assume that αj and ηj are a priori independent such
that π(Ω) = π(β)π(α1 )π(α2 )π(η1 )π(η2 ). Then the posterior distributions of the
above two regression models are

P1 (β, α1 , α2 , η1 , η2 |D) ∝ L1 (D|β, α1 , α2 , η1 , η2 )π(β)π(α1 )π(α2 )π(η1 )π(η2 ), (5.5.5)

and

P2 (β, α1 , α2 , η1 , η2 |D) ∝ L2 (D|β, α1 , α2 , η1 , η2 )π(β)π(α1 )π(α2 )π(η1 )π(η2 ) (5.5.6)

respectively. It is often of interest to explore the propriety of the posterior distribution when an improper uniform prior is used on β, i.e., π(β) ∝ 1. Chen et al. [14]
established the propriety of the posterior distribution of the bounded cumulative
hazard model under some general conditions. In the following two theorems, we
prove that, under similar conditions, the posterior distributions (5.5.5) and (5.5.6)
are proper.
Theorem 5.5.1. Let d1 =

Pn

i=1 δi1

and d2 =

Pn

i=1 δi2 .

Let X∗ be an n × m matrix

with rows δi1 x′i . Consider the posterior distribution given in (5.5.5) under the complementary log-log link with an improper prior π(β) ∝ 1. A sufficient condition for
this posterior distribution to be proper is that
(a) X∗ is of full rank;
ν −1

(b) π(αj ) ∝ αj j

exp(−τj αj ), j = 1, 2, where τj > 0 and νj > −dj ;
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(c) π(ηj ), j = 1, 2, is proper.
Proof. Note that the likelihood function (5.5.2) can be written as

L1 (D|Ω) =

n
Y

(θ1i (xi , β)f01 (ti |γ1 ) exp(−θ1i (xi , β)F01 (ti |γ1 )))δi1

i=1

× (θ2i (xi , β)f02 (ti |γ2 ) exp(−θ2i (xi , β)F02 (ti |γ2 )))δi2
× (S(ti |xi , β, γ1 , γ2 ))1−δi1 −δi2 .

(5.5.7)

Chen et al. [14] showed that if f and F are the density and distribution function of
a Weibull distribution of the form (5.5.4), there is some positive constant M such
that
(θi f (ti |α, η) exp(−θi F01 (ti |α, η)))δi ≤ αδi M,

(5.5.8)

and that if further θi = exp(x′i β) and X ∗ = (δ1 x′1 , . . . , δn x′n )′ is of full rank, there is
some positive constant K ∗ such that
Z

Rm

n
Y

(θi f (ti |α, η) exp(−θi F01 (ti |α, η)))δi dβ ≤ α

P

δi

K ∗.

(5.5.9)

i=1

Then, by (5.5.8), the likelihood function (5.5.7) is bounded by

L1 (D|Ω) ≤

α2d2 M ∗

n
Y

(θ1i (xi , β)f01 (ti |γ1 ) exp(−θ1i (xi , β)F01 (ti |γ1 )))δi1 , (5.5.10)

i=1

where M ∗ is some positive constant. And next, by (5.5.9),
Z

Rm

L1 (D|Ω)dβ ≤ α1d1 α2d2 M ∗ K ∗ .

(5.5.11)
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As a result, we have
Z

∞

0

∝

Z

Z

0

∞

Z

∞

∞

Z

Z

P1 (β, α1 , α2 , η1 , η2 |D)dα1dα2 dη1 dη2 dβ

0
−∞ −∞ Rm
∞Z ∞Z ∞ Z ∞ Z
0

−∞

−∞

L1 (D|β, α1 , α2 , η1 , η2 )π(β)π(α1 )π(α2 )

Rm

×π(η1 )π(η2 )dα1 dα2 dη1 dη2 dβ
Z ∞Z ∞Z ∞ Z ∞
∗ ∗
≤M K
α1d1 α2d2 π(α1 )π(α2 )π(η1 )π(η2 )dα1 dα2 dη1 dη2 < ∞
0

0

−∞

−∞

by conditions (b) and (c) in the theorem.

Theorem 5.5.2. Let d1 =

Pn

i=1 δi1

and d2 =

Pn

i=1 δi2 .

Let X∗ be an 2n × m matrix

with rows δi1 x′i and δi2 x′i . Consider the posterior distribution given in (5.5.6) under
the logistic link with an improper prior π(β) ∝ 1. A sufficient condition for this
posterior distribution to be proper is that
(a) X∗ is of full rank;
ν −1

(b) π(αj ) ∝ αj j

exp(−τj αj ), j = 1, 2, where τj > 0 and νj > −dj ;

(c) π(ηj ), j = 1, 2, is proper.
Proof. Since X∗ is of full rank, there exist m linearly independent rows x′n1 , . . . , x′nm
P
such that δnj 1 + δnj 2 = 1 for each j = 1, . . . , m. Assume that m
j=1 δnj 1 = m1 and
Pm
j=1 δnj 2 = m2 , where m1 + m2 = m. Note that the likelihood function (5.5.3)
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can also be written in the form of (5.5.7). Then, by (5.5.8), there is some positive
constant M ∗ such that
L2 (D|Ω) ≤ α1d1 −m1 α2d2 −m2 M ∗
m1
Y


×
θ1nj (xnj , β)f01 (tnj |γ1 ) exp(−θ1nj (xnj , β)F01 (tnj |γ1 ))
×

j=1
m2
Y

[θ2nk (xnk , β)f02 (tnk |γ2 )

k=1

× exp(−θ2nk (xnk , β)F02 (tnk |γ2))].

(5.5.12)

Therefore, the proof can be completed if we can show that there is some positive
constant K ∗ such that
Z

m1
Y

θ1nj (xnj , β)f01 (tnj |γ1 ) exp(−θ1nj (xnj , β)F01 (tnj |γ1 ))

Rm j=1
m2
Y

×



(θ2nk (xnk , β)f02 (tnk |γ2 ) exp(−θ2nk (xnk , β)F02 (tnk |γ2 ))) dβ

k=1

≤ α1m1 α2m2 K ∗ .

(5.5.13)

To proceed, we do transformations uj = x′nj β and uk = x′nk β for j = 1, . . . , m1 and
k = 1, . . . , m2 . Then
Z

m1
Y

θ1nj (xnj , β)f01 (tnj |γ1) exp(−θ1nj (xnj , β)F01 (tnj |γ1 ))

Rm j=1
m2
Y



(θ2nk (xnk , β)f02 (tnk |γ2 ) exp(−θ2nk (xnk , β)F02 (tnk |γ2 ))) dβ

×

k=1

∝

m1 Z
Y

∞




log(1 + euj )f01 (tnj |γ1 )(1 + euj )−F01 (tnj |γ1 ) duj

j=1 −∞
m2 Z ∞
Y

×

k=1

−∞


log(1 + e−uk )f02 (tnk |γ2 )(1 + e−uj )−F02 (tnk |γ2 ) duk . (5.5.14)
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Now, we show that there are positive constants K1 and K2 such that
m1 Z
Y
j=1

∞
−∞



uj
uj F01 (tnj |γ1 )
duj ≤ α1m1 K1
log(1 + e )f01 (tnj |γ1 )(1 + e )

(5.5.15)


log(1 + e−uk )f02 (tnk |γ2 )(1 + e−uj )F02 (tnk |γ2) duk ≤ α2m2 K2 .

(5.5.16)

and
m2 Z
Y
k=1

∞

−∞

We do another transformation, wj = 1 + euj , and we have
Z

∞

−∞



uj −F01 (tnj |γ1 )

uj

log(1 + e )f01 (tnj |γ1 )(1 + e )

= f01 (tnj |γ1 )

Z

∞

1

−F01 (tnj |γ1 )

(log wj )wj
wj − 1



duj

dwj .

(5.5.17)

We claim that there is a positive constant Q such that
Z

∞

1

≤ Q

Z

1

−F01 (tnj |γ1 )

(log wj )wj
wj − 1
∞

dwj

−F01 (tnj |γ1 )

(log wj )wj
wj

dwj = Q

Z

∞

1

(log wj )
dwj .
1+F01 (tnj |γ1 )
wj

(5.5.18)

To prove (5.5.18), let a > 1 be arbitrary. Note that
−F01 (tnj |γ1 )

(log wj )wj
wj − 1

<∞

(5.5.19)

for wj ∈ [1, a] and hence
Z

a
1

−F01 (tnj |γ1 )

(log wj )wj
wj − 1

dwj < ∞.

(5.5.20)
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Since we also have
Z

a
1

−F01 (tnj |γ1 )

(log wj )wj
wj

dwj < ∞,

(5.5.21)

there is a constant Q1 such that
Z

a

1

−F01 (tnj |γ1 )

(log wj )wj
wj − 1

dwj ≤ Q1

Z

1

a

−F01 (tnj |γ1 )

(log wj )wj
wj

dwj .

(5.5.22)

Since there exists a constant Q2 > a/(a − 1) such that
−F01 (tnj |γ1 )

(log wj )wj
wj − 1

−F01 (tnj |γ1 )

(log wj )wj
≤ Q2
wj

(5.5.23)

for wj ≥ a > 1, we have
Z

a

∞

−F01 (tnj |γ1 )

(log wj )wj
wj − 1

dwj ≤ Q2

Z

a

∞

−F01 (tnj |γ1 )

(log wj )wj
wj

dwj .

(5.5.24)

Thus, (5.5.18) is proved by (5.5.22) and (5.5.24). Now we claim that there is a
positive constant Q∗ such that
Z

1

∞

(log wj )
1+F01 (tnj
wj

dwj ≤
|γ1 )

Q∗ α1
.
f01 (tnj |γ1 )

(5.5.25)

To proceed, note that for ∀ǫ > 0,
log wj
→ 0, as wj → ∞.
wjǫ

(5.5.26)

So there is a constant bǫ > 1 such that
log wj
< 1, for wj > bǫ .
wjǫ

(5.5.27)
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Let 0 < ǫj < F01 (tnj |γ1 ). Then there is a constant bǫj > 1 such that
(log wj )
1+F01 (tnj |γ1 )
wj

<

1

(5.5.28)

1+F01 (tnj |γ1 )−ǫj
wj

for wj > bǫj . And hence,
∞

Z

bǫj

(log wj )
1+F01 (tnj
wj

dwj ≤
|γ1 )

Z

∞

bǫj

1
1+F01 (tnj |γ1 )−ǫj
wj

dwj .

(5.5.29)

Since we have both
Z

bǫj

1

(log wj )
dwj
1+F01 (tnj |γ1 )
wj

<∞

(5.5.30)

and
Z

bǫj

1
1+F01 (tnj |γ1 )−ǫj
wj

1

dwj < ∞,

(5.5.31)

there is a constant Q∗1 such that
Z

bǫj

1

(log wj )
1+F01 (tnj
wj

dwj ≤
|γ1 )

Q∗1

Z

bǫj

1
1+F01 (tnj |γ1 )−ǫj
wj

1

dwj .

(5.5.32)

Therefore, (5.5.29) and (5.5.32) imply that there is a positive constant Q∗2 such that
Z

1

∞

(log wj )
1+F01 (tnj

wj

dwj ≤
|γ1 )

Q∗2

Z

∞
1

1
1+F01 (tnj

wj

dwj =
|γ1 )−ǫj

Q∗2
.
F01 (tnj |γ1 ) − ǫj

(5.5.33)

Chen et al. [14] showed that if f and F are the density and distribution function of
a Weibull distribution of the form (5.5.4), then there is a constant K such that
f (ti |γ)
≤ αK.
F (ti |γ)

(5.5.34)
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In other words, we have
F01 (tnj |γ1 ) ≥
Let ǫj =

f01 (tnj |γ1 )
.
2α1 K

Z

1

∞

(5.5.35)

Then

(log wj )
1+F01 (tnj

wj

f01 (tnj |γ1 )
.
α1 K

dwj ≤
|γ1 )

Q∗2
2α1 KQ∗2
≤
.
F01 (tnj |γ1 ) − ǫj
f01 (tnj |γ1 )

(5.5.36)

This proves (5.5.25). Furthermore, (5.5.25) together with (5.5.18) proves that
Z

∞

−∞




log(1 + euj )f01 (tnj |γ1 )(1 + euj )−F01 (tnj |γ1) duj ≤ QQ∗ α1 .

(5.5.37)

Hence, (5.5.15) is proved. And (5.5.16) can be proved in a similar way. As a result,
(5.5.13) is proved. So is the theorem.
The conditions in these two theorems are quite general and typically satisfied
for most datasets. They enable us to carry out non-informative Bayesian inference
on the regression coefficients and recover the maximum likelihood estimates.

5.5.2

The Bayesian Posterior Estimator

Once the posterior distributions of the model parameters are obtained, the problem remains on how to get an estimate for the cumulative incidence function, the
cure rate and the overall survival function. For ease of illustration, we consider the
(l)

(l)

(l)

case of two competing risks without a regression model. Let αj , ηj , pj , j = 1, 2,
l = 1, . . . , L, be the obtained posterior samples of the parameters, where L is the
number of posterior samples. One straightforward way is to calculate the posterior
mean or median for each parameter. Suppose that α̂j , η̂j , p̂j , j = 1, 2, are the

83
posterior estimates obtained from the posterior samples in such a way. Note that
p̂1 and p̂2 should satisfy p̂1 + p̂2 = 1. Then a plug-in estimator for each cumulative
incidence function is given by

F̂j (t) = 1 − (1 − p̂j )F̂0j (t|α̂j ,η̂j ) , j = 1, 2.

(5.5.38)

Similarly, a plug-in estimator for the overall survival function can be obtained by
plugging in the posterior estimates of the parameters into (5.4.2). A plug-in estimator for the cure rate for each risk can be obtained by plugging the posterior
estimates of the parameters into (5.3.4), which can be calculated using Monte Carlo
methods. The plug-in estimators are convenient to calculate. However, they are not
obtained from a strictly Bayesian perspective.
To obtain a Bayesian estimator of the cumulative incidence function, we need
to evaluate the cumulative incidence function using each pair of posterior samples.
For each t, let

(l)

(l)

(l)

(l)

Fj (t) = 1 − (1 − pj )F0j (t|αj

(l)

,ηj )

, j = 1, 2.

(5.5.39)

Then a Bayesian posterior estimator of the cumulative incidence function can be
obtained as
L

1 X (l)
F (t), j = 1, 2.
F̃j (t) =
L l=1 j

(5.5.40)

We notice that F̃j (t) has the desired properties of a cumulative incidence function.
It is non-decreasing and satisfies F̃j (0) = 0 and F̃1 (t) + F̃2 (t) → 1 as t → ∞. Using
this estimator, the Bayesian posterior estimator of the overall survival function is
simply S̃(t) = 1 − F̃1 (t) − F̃2 (t). To get a Bayesian posterior estimator of the cure
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rate, we need to evaluate (5.3.4) with each of the L pairs of posterior samples to
P
(l)
(l)
obtain cj , l = 1, . . . , L, and calculate the estimator as c̃j = Ll=1 cj /L.
Although the plug-in estimator and the Bayesian estimator may sometimes give

similar results, in general, the plug-in estimator is less optimal than the Bayesian
estimator, since it is not guaranteed to be posterior mean or median of the quantity
it estimates. Furthermore, we can easily get the posterior credible interval of the
quantity of interest from the estimation process of a Bayesian estimator. On the
other hand, to calculate a posterior credible interval from plug-in estimation is
problematic. The Bayesian estimator has one potential disadvantage in that its
calculation is more time consuming. To mitigate this problem, we can thin the
posterior samples and use, say, every 5th iteration instead of all of the L posterior
samples in our calculation.

5.6

5.6.1

Simulation and Data Analysis

Simulation Studies

In this subsection, we conducted a simulation study to show the performance
of our proposed model for cumulative incidence function. In our simulation, we
assumed there are two competing risks and subjects may be cured from the first risk.
The times to event for the two risks were generated from two independent Weibull
distribution. The event times for the first risk were generated from Weibull(α1∗ =
1.5, η1∗ = −2.7) and the second from Weibull(α2∗ = 0.8, η2∗ = −1.3). The times to first
event and the causes were recorded as the dataset for analysis. In each simulation,
we generated 100 such datasets. We replicated the simulation with cure rate 20%
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and 50% for the first risk and with sample size per dataset 100 and 200. There was
no covariate involved in the simulation. We did not assume any censoring in the
simulation.
In the above simulation set-up, the actual cumulative incidence functions for
the two risks are complicated and do not have closed forms. In the analysis of the
generated data, we used our proposed model, in which F01 and F02 were modeled
as Weibull(α1 , η1 ) and Weibull(α2 , η2 ) of the form (5.5.4) respectively. It should
be pointed out that our analysis model is thus different from the data-generating
model. We assigned Gamma(0.1, 0.1) prior on α1 and α2 , N(0, 100) prior on η1 and
η2 , and Uniform(0, 1) prior on p1 . In each estimation, we retained 10,000 posterior
samples after appropriate burn-in. The cure rates and the cumulative incidence
functions were estimated using the Bayesian estimator as discussed in Subsection
5.5.2. For comparison, we also used the mixture cure model (3.2.1) to estimate the
cure rate for the first risk. In the mixture cure model, S0 (t) is modeled using the
Weibull distribution (5.5.4) and the same prior distributions as above. The cure
rate c is assigned a Uniform(0, 1) prior.
The 4th and the 5th columns of Table 5.1 are the estimated cure rates for the
two risks. The estimates are the average of the Bayesian estimators obtained from
each dataset. We see that our model correctly distinguished the curable risk from
the incurable risk. In addition, the estimated cure rates were close to the true
values. The last column in the table contains the estimated cure rates (which are
also the average of posterior mean obtained from each dataset) for the first risk
using a competing risks mixture cure model. Note that the mixture cure model is
the true model for our data-generating process. We observe that the estimates from
our model are not significantly inferior to those from the mixture cure model when
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the true cure rate is 20% and are even slightly better when the true cure rate is
50%.

Table 5.1: Estimated cure rates from simulated data.

N
100
200
100
200

Data Generating
Value
Risk 1 Risk 2
0.2
0.0
0.2
0.0
0.5
0.0
0.5
0.0

Our Proposed
Model
Risk 1 Risk 2
0.196 0.003
0.217 <.001
0.466 <.001
0.487 <.001

Mixture Cure
Model
Risk 1
0.201
0.210
0.451
0.473

Figures 5.1 - 5.4 show the estimated cumulative incidence functions overlaid
with actual ones. The plotted curves are the average of the posterior mean curves
obtained from each dataset. The upper curve is for the second risk and the lower
one is for the first risk. Since the actual cumulative incidence functions are not in
closed forms, we calculated them using Monte Carlo methods at each time point.
As a result, the obtained curves are not smooth and contain small fluctuations,
particularly toward the tail. Nevertheless, from these plots, we clearly see that
estimated cumulative incidence curves from our model are extremely close to the
true curves. This demonstrates the ability of our proposed model to approximate
the true model given a reasonable sample size.
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Figure 5.1: Estimated cumulative incidence function with sample size
100 and cure rate 20%.
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Figure 5.2: Estimated cumulative incidence function with sample size
200 and cure rate 20%.
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Figure 5.3: Estimated cumulative incidence function with sample size
100 and cure rate 50%.
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Figure 5.4: Estimated cumulative incidence function with sample size
200 and cure rate 50%.

To further examine the performance of our model, we compared the estimated
cumulative incidence functions from our model with the nonparametric estimator
(Aalen [2]) in terms of the distances from the true curves. We define the distance
between the estimated and the actual cumulative incidence functions as

d(Fj , F̂j ) = sup |Fj (t) − F̂j (t)|,
t∈Tj

(5.6.1)
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where Tj denotes the set of observed event times from the jth risk. This is a typical
definition of the distance between two probability distributions. The supremum is
taken over observed event times because the nonparametric estimates are obtained
only at such time points. Since the nonparametric estimator of the cumulative
incidence function is a step function, its distance from the true function will be
larger if the supreme is taken over all time points. Table 5.2 shows the calculated
distances, which are the average over all the simulated datasets. It can be seen that
the estimates from our model are better in most of the cases. These results suggest
that our model can potentially perform better than the nonparametric method in
estimating the true cumulative incidence curve.

Table 5.2: Distance between the estimated and the actual cumulative incidence
functions.

Sample Size
100
200
100
200

Nonparametric Estimator
Risk 1
Risk 2
0.0490
0.1134
0.0421
0.0543
0.0546
0.0496
0.0201
0.0565

Proposed
Risk 1
0.0438
0.0308
0.0367
0.0283

Estimator
Risk 2
0.0540
0.0387
0.0515
0.0392
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5.6.2

Analysis of Hodgkin’s Disease Data

The dataset consists of records of 865 patients treated for Hodgkin’s disease
at the Princess Margaret Hospital in Canada and followed for a maximum of 36
years. The complete dataset was published by Pintilie [77] and can be downloaded
from the author’s website. All patients have early stage disease and were treated
either with radiation (RT) or radiation and chemotherapy (CMT). Some patients
were diagnosed with a second malignancy after the Hodgkin’s disease. Pintilie [77]
considered first relapse, second malignancy and death to be three competing risks.
However, in our study, we only consider death to be the single endpoint and we treat
death from Hodgkin’s disease and death from other causes as two competing risks.
Of 865 patients, 131 died from Hodgkin’s disease and 187 died from other causes.
The rest were still alive at the end of the study. We used the same model and the
same prior distributions as those in the simulation studies except that the prior
support of η1 and η2 were restricted to [-60, 60] to improve the posterior sampling.
Figure 5.5 plots the estimated cumulative incidence curves for these two risks
from our model. Figures 5.6 and 5.7 show the estimated 95% credible intervals for
the two curves. Figure 5.8 contains the plot of the estimated overall survival curve
along with the 95% credible interval. In each of these plots, our estimated curves
are overlaid with the nonparametric estimates for comparison. In each case, our
estimates and the nonparametric estimates are quite close to each other. This indicates that our model has very satisfactory goodness-of-fit. In Figure 5.5, we see that
the cumulative incidence for death from Hodgkin’s disease levels off quickly while
the cumulative incidence for death from other causes increases gradually during the
observation period. This phenomenon reasonably reflects the reality because each
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person will eventually die from some cause even if he/she is cured from Hodgkin’s disease. Let p1 and p2 denote the probabilities of eventually dying from the Hodgkin’s
disease and from the other causes respectively. The estimated p̂1 and p̂2 are 15.7%
and 84.3% respectively. These two figures represent the long-term probabilities of
observing an event from each of the two risks.
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Figure 5.5: Estimated cumulative incidence function for Hodgkin’s
disease data.
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Figure 5.6: Estimated credible interval for cumulative incidence of
death from Hodgkin’s disease.
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Figure 5.7: Estimated credible interval for cumulative incidence of
death from other causes.
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Figure 5.8: Estimated overall survival function for Hodgkin’s disease
data.

Table 5.3 displays the estimated cure rates along with the 95% credible intervals
for the two risks. In our context, “cure” means survival, but not disease-free survival.
Our model and the mixture cure model give similar estimates on the cure rate for
Hodgkin’s disease. Given the data, 83.5% of the patients were estimated to be cured
from the Hodgkin’s disease. In this example, we see that the estimated cure rate
is very close to 1 − p̂1 , where p̂1 is the estimated limiting value of the cumulative
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incidence function of dying from Hodgkin’s disease. This is because the progression
of the other risk is much slower than the Hodgkin’s disease. Therefore, if a subject
is not cured from the Hodgkin’s disease, the probability is low that he/she will be
censored by the other risk. Using our model, the estimated cure rate for other causes
is 2 × 10−5 with 95% credible interval (3 × 10−22 ,1 × 10−4 ), which essentially means
no cure and is consistent with the reality. Table 5.3 also shows the estimated cure
rate for other causes with a mixture cure model. As is seen, the estimate is quite
unreliable. The wide credible interval also suggests that this estimate is problematic.
From Figure 5.5, the nonparametric estimate of the cumulative incidence of other
causes displays a short plateau toward the end of the observation period. Thus, one
may be tempted to think that a cure rate might exist. But it does not. This tells
us that we must keep in mind the nature of the risk when assessing whether it is
curable or not. This also tells us that the cure model should only be applied to
situations where we have prior knowledge that the risk of interest can be cured.

Table 5.3: Estimated cure rates from Hodgkin’s disease data.
Risk
Hodgkin’s Disease
Other Causes

Proposed Model
0.835 (0.807, 0.861)
<.001 (<.001, <.001)

Mixture Cure Model
0.836 (0.809, 0.861)
0.293 (0.017, 0.565)

To investigate the covariate effects on the cumulative incidence functions, we
built the two regression models introduced in Section 5.4. We considered two covariates: treatment and gender. Of 865 subjects, 249 were treated with CMT and
the rest with RT; 402 are females and 463 are males. Table 5.4 shows the estimated
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parameters for the complementary log-log model. Table 5.5 shows the estimated parameters for the logistic model. The two models give consistent results. Both show
that neither treatment nor age has a significant effect on the cumulative incidence
functions.

Table 5.4: Parameter estimates from regression model 1.
Parameter
Treatment (RT=1)
Gender (Male=1)

Posterior Mean
-0.236
-0.014

95% Credible Interval
(-0.573, 0.102)
(-0.338, 0.309)

Table 5.5: Parameter estimates from regression model 2.
Parameter
Treatment (RT=1)
Gender (Male=1)

5.7

Posterior Mean
-0.260
-0.010

95% Credible Interval
(-0.638, 0.132)
(-0.362, 0.342)

Discussion

In this chapter, we proposed a new model that directly models the cumulative
incidence function. Our model has several advantages. First, it gives a closed-form
expression for the cumulative incidence function. Second, it ensures that the sum
of the cumulative incidence functions has a limit of one. Third, it accommodates
both parametric and semi-parametric models. Fourth, it allows flexible regression
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modeling on the covariates and has a proportional hazard structure. Fifth, the
hazard function corresponding to the cumulative incidence function can be either
monotone or unimodal. Sixth, the model allows the use of noninformative priors on
the regression parameters. And finally, it admits the possibility that a subset of all
the risks can be cured. The simulation shows that our model is a good approximation
to the true model when it is misspecified. Although we only considered Weibull
distribution, other types of distributions can also be used.
There are several immediate topics for future research. Our model can be readily
extended to incorporate the dependence among subjects. Since our model is fully
likelihood based, it can also handle longitudinal data although the computation will
definitely be more complicated. More importantly, our study showed the promise of
using cure models to model the cumulative incidence functions. This opens up the
possibility of applying a richer class of models for the cumulative incidence functions.

CHAPTER 6
FUTURE RESEARCH

6.1

Introduction

In this dissertation, we have proposed a novel competing risks model and a
novel cure model. We have shown that our proposed competing risks model and
cure models have favorable properties. Our proposed competing risks model gives
a closed-form expression and proportional hazard structure for the cumulative incidence functions, ensures the propriety of the overall survival function and automatically identifies risks that have a cure fraction. Our proposed cure model is
stochastically ordered, has a closed-form and analytically tractable expression and
includes several existing models as special cases.

6.2

Frailty Models

Both of our proposed models can be extended to incorporate additional subject
heterogeneity and to a multivariate version by means of a frailty model. Frailtybased competing risks models and cure models have an extensive literature. Some
recent developments in these areas include, but are not limited to, Chen, Kramer,
Greene and Rosenberg [13], Chen et al. [15], Diao and Yin [25], Dixon, Darlington
and Edge [26], Gorfine and Hsu [39], Ha, Christian, Jeong, Park and Lee [42], Hsu,
Gorfine and Malone [45], Yin [103, 104], and Yu [107]. Such extensions will provide
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more robust and powerful inference on inter-subject heterogeneity and correlated
survival times.

6.2.1

Bivariate Frailty Cure Models

Let T = (T1 , T2 ) be a bivariate failure time. The bivariate bounded cumulative
hazard function given by Chen et al. [15] is

S(t1 , t2 |w) = exp(−w[θ1 F1 (t1 ) + θ2 F2 (t2 )]),

(6.2.1)

where F1 (t) and F2 (t) are two independent distribution functions of some nonnegative random variables, θ1 > 0, θ2 > 0, and w > 0 is the frailty parameter
that induces the correlation between T1 and T2 . The cure rate associated with each
failure type is given by exp(−θ1 ) and exp(−θ2 ) respectively. Now, let a 6= 0 and
consider a Box-Cox transformation of the form

Sa (t1 , t2 |w)a − 1
exp(−aw[θ1 + θ2 ]) − 1 exp(−aw[θ1 S1 (t) + θ2 S2 (t)]) − 1
=
−
.
a
a
a
Then, as a → 0, we get

log Sa (t1 , t2 |w) = −w(θ1 + θ2 ) − (−w[θ1 S1 (t1 ) + θ2 S2 (t2 )])
= −w[θ1 F1 (t1 ) + θ2 F2 (t2 )].

Hence, we obtain the bivariate bounded cumulative hazard model as

102

lim Sa (t1 , t2 |w) = exp(−w[θ1 F1 (t1 ) + θ2 F2 (t2 )]).

a→0

By rearranging the terms in the above Box-Cox transformation, we then derive a
new class of bivariate frailty cure models in the form of

1
Sa (t1 , t2 |w) = 1 + e−aw(θ1 +θ2 ) − e−aw(θ1 S1 (t1 )+θ2 S2 (t2 )) a .

(6.2.2)

Properties of this model are under investigation and are expected to be similar to
those of our proposed model in Section 4.

6.2.2

Competing Risks Frailty Models

Suppose that subjects are clustered into n groups with mi , i = 1, . . . , n, subjects
in each group and that survival data from subjects within the same group are correlated. Then such correlation can be modeled by a shared frailty model. In the
bounded cumulative hazard model, the hazard function for the jth subject in the
ith group has the form
h(tij |wi ) = f (tij )wi θij ,
where wi is the unobserved frailty variable for the ith group.
This formulation can also be applied to our proposed competing risks models
for clustered data. For the jth subject in the ith group, the cumulative incidence
function for the kth risk can be modeled as
Fk (tij ) = 1 − e−wi θij F0k (tij ) = 1 − (1 − pijk )wi F0k (tij ) ,

(6.2.3)
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where each F0k (tij ) is a proper distribution function and pijk ’s satisfy that
K
X

pijk = 1

k=1

for all i = 1, . . . , n and j = 1, . . . , mi . The regression models we introduced in Chapter 5 can also be used on each pijk here. This model allows us to study the association
between the individual cumulative incidence rates within clusters of subjects.

6.3

Longitudinal Models

In addition, both of our proposed models can be extended to accommodate
longitudinal data. In medical studies, longitudinal measurements on biomarkers
are often collected in addition to survival data. These longitudinal data provide
additional information on the survival status of the patients and enable more efficient
estimation. Joint modeling of longitudinal measurements and survival data has been
challenging. Incorporating longitudinal data into a cumulative incidence function
model has been particularly difficult.
Chen et al. [16] developed a joint model of longitudinal data and survival times
under the bounded cumulative hazard formulation. Given the fact that our proposed
cure model and competing risks model are both closely related to the bounded cumulative hazard model, the formulation in Chen et al. [16] can be directly extended
to our proposed models. In particular, the ability of our proposed cumulative incidence function model to accommodate longitudinal data is a distinct feature among
existing models in the current literature.
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